Prostaglandins of urogenital origin by Horton, Eric William
PROSTAGLANDINS OF UROGENITAL ORIGIN
by
Eric William Horton
B.Sc., M.B. Ch.B., Ph.D., D.Sc
Thesis submitted for
the Degree of Doctor of Medicine





1. Prostaglandins from the Kidney - a study 12
of the output of prostaglandins from the
rabbit kidney in vivo
2. Prostaglandins from the Male Reproductive 43
Tract - a study of the daily output of
prostaglandins in human semen and the
effects of treatment with high doses of
aspirin
3. Prostaglandins from the Female Reproductive 55
Tract - a study of the output of prostaglan¬
dins by the guinea-pig uterus under various
conditions and the role of prostaglandin F2a






Prostaglandins were discovered by the Swedish
scientist Ulf von Euler, who observed pharmacological
effects with semen and prostatic/vesicular extracts
and established beyond doubt that the active principle,
which he named prostaglandin, belongs to a completely
new group of naturally-occurring substances (von Euler,
1934, 1935, 1936, 1939). Others had observed this
biological activity previously but had not pursued
the investigation much further than reporting the
phenomenon.
It was another two decades before the active
principles were isolated by BergstrOm and Sj'Ovall
(1960a, b). Isolation of two prostaglandins (Ej
and F, a), assigned the empirical formulae C2oH3405
and C2oH3605 respectively, was followed by the
elucidation of their full chemical structures (BergstrOm,
Ryhage, Samuelsson and Sjbvall, 1963). This work pro¬
vided a tremendous impetus to biological research and
the field has advanced rapidly in the past 15 years.
The biosynthesis of prostaglandins from arachidonic
acid, and from its precursor, dihomo-gamma-linolenic
acid, was discovered independently by van Dorp,
Beerthius, Nugteren and Vonkeman (1964) and by BergstrOm
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Danielsson and Samuelsson (1964) (Fig. 1). Inhib¬
ition of prostaglandin biosynthesis by aspirin,
indomethacin and pharmacologically-related drugs
was subsequently reported by Vane and his colleagues
(Vane, 1971; Ferreira, Moncada and Vane, 1971;
Smith and Willis, 1971).
Meanwhile the prostaglandin field developed on
three main lines: (1) the discovery of their
pharmacological actions on numerous biological systems
including the kidney and the uterus (see Horton, 1965,
1969, 1972; Bergstrbm, Carlson and Weeks, 1968;
Ramwell, 1973, 1975, 1977; Karim, 1975, 1976a, b):
(2) the discovery of their presence (and biosynthesis)
in virtually every animal tissue investigated (see
Bergstrom and Samuelsson, 1965; Bergstrom and Bernhard,
1973; Samuelsson and Paoletti, 1976), and (3) the
discovery of their release from organs in response to
a variety of chemical and physical stimuli (see Ramwell
and Shaw, 1967, 1970; Vane, 1969; Horton, 1972).
All these findings tended to suggest that prostaglandins
might have local regulatory functions in different
biological systems. For the most part any role as a
circulating hormone seemed to be ruled out by the
observation that as much as 90 to 95% of infused
prostaglandins E2 and F2(X is removed by a single passage
through the pulmonary circulation (Ferreira and Vane,
1967), although this argument may not apply to prosta¬
glandins of the A series which are not removed in this
way (Horton and Jones, 1969).































Figure 1 Biosynthesis of Prostaglandins
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Interest has long focussed upon the possible
physiological and pathophysiological roles of prosta¬
glandins. In this study three of these have been
investigated. All relate to organs of the urogenital
tract.
Adrenergic Nerve Terminals As early as 1938 von Euler
had shown that in the rabbit, pressor responses to
adrenaline are reduced following prostaglandin adminis¬
tration (von Euler, 1938). When pure prostaglandin E1
became available, this observation was confirmed
(Holmes, Horton and Main, 1963). Similar effects were
observed, however, on vascular responses to noradrenaline,
vasopressin and angiotensin. It was therefore postulated
that PGE, acts upon a point in the final common path for
the actions of all these vasoconstrictor drugs. A simi¬
lar conclusion was reached simultaneously by Steinberg,
Vaughan, Nestel and Bergstrom (1963) from their work on
the rat epididymal fat pad in. vitro. At the Nobel
Symposium on Prostaglandins in 1966 it was proposed,
from this and other evidence, that the mode of action
of PGE, is to inhibit adenylate cyclase (Steinberg and
Vaughan, 1967; Butcher, Pike and Sutherland, 1967).
At the same symposium Ramwell and Shaw (1967) reported
that adrenergic nerve stimulation releases a prosta-
glandin-like substance from the rat epididymal fat pad
in vitro. Thus a physiological mechanism was proposed
in which the actions of noradrenaline released on nerve
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stimulation are partly inhibited by simultaneously
released prostaglandins of the E series, that is by a
post-synaptic effect.
All these experiments were _in vitro on saline-
perfused tissues. We therefore decided to investigate
these phenomena in another adrenergically-innervated
organ but in vivo. Electrical stimulation of the
blood-perfused dog spleen resulted in an enormous out¬
put of prostaglandin E2 (Davies, Horton and Withrington,
1968) though other lipids including a prostaglandin F-like
substance were also released. The post-synaptic hypoth¬
esis was then investigated in the same preparation by
infusing prostaglandins intra-arterially. Little or
no effect on splenic responses to either noradrenaline
or electrical stimulation using either prostaglandin E,
or prostaglandin E2 could be detected (Davies and
Withrington, 1968). The hypothesis of Ramwell and Shaw
did not appear to extend to the dog spleen. However,
encouraged by our observations on release, Hedqvist
(1969) studied the effect of prostaglandin E2 on the
perfused cat spleen. He too detected little effect
on the responses to noradrenaline but the responses to
electrical stimulation of the nerve were greatly dimin¬
ished during prostaglandin E2 infusion. He demonstrated
that this was a pre-synaptic action resulting in a
reduction of transmitter outflow. This in turn led to
the hypothesis that adrenergic nerve stimulation
releases not only noradrenaline but also (as in the dog
spleen) prostaglandin E2 and that this prostaglandin
exerts a physiological role by reducing the amount
of transmitter released from adrenergic neurones on
continued electrical stimulation (as in the cat
spleen) (Hedqvist, 1971, 1973).
The arguments for and against Hedqvist's hypothesi
have been presented previously (Horton, 1973, 1976a).
The chief weaknesses in the evidence have been the lack
of conclusive identification of the prostaglandin
actually released (notably from the cat spleen) and
the necessity to use evidence from different organs
and species in order to present a unified hypothesis.
The need to overcome both these criticisms was the
reason for the investigation presented in part 1 of
the Experimental Section of this thesis.
Human Seminal Prostaglandins
Prostaglandins were first discovered in human
semen where they occur in higher concentrations than in
any other known mammalian tissue or tissue fluid.
From the earliest times it has been suggested that
they might have some role in reproduction and possibly
be essential for full fertility of the human male
(von Euler, 1939, 1966; Asplund, 1947; Eliasson, 1959
Hawkins and Labrum, 1961). Evidence in support of this
contention has been presented by Bygdeman, Fredricsson,
Svanborg and Samuelsson (1970) who showed that the
seminal prostaglandin E concentration of men in inferti
marriages with no abnormal clinical or laboratory
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findings was lower (18 |ig/ml) than that of men of
proven recent fertility (54 jog/ml), a difference that
was highly significant statistically.
The mechanism by which prostaglandin E compounds
aid conception is unknown, there have been many specu¬
lations but few positive results of relevance. Inter¬
actions of prostaglandins with sperm, effects on seminal
vesicle emptying and effects on the female reproductive
tract following sexual intercourse have all been invoked.
Certainly the possibility that biologically active sub¬
stances such as the prostaglandins may be produced in
one individual of the species (the male) and exert
their physiological action upon target organs in a
second individual (the female) is interesting as a
biological mechanism. It would place the seminal
prostaglandins in a category somewhat analogous to
pheromones (Horton, Main and Thompson, 1963). Von Euler
(1966) coined the name 'exohormone' for substances of
this type.
The discovery of biosynthesis inhibition by drugs
such as aspirin, referred to above, provided a readily
available tool for investigators wishing to study the
physiological roles of prostaglandins in animals and
man. In part 2 of the Experimental Section of this
thesis the levels of seminal prostaglandins were
measured in human volunteers before, during and after
the administration of aspirin for a three-day period,
to see how far it was possible to induce changes similar
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to those observed in the apparently healthy but
infertile males referred to above.
Prostaglandins and the Uterine Luteolytic Hormone
One of the many unexpected biological properties
of the prostaglandins was reported by Pharriss and
Wyngarden (1969) who first showed that prostaglandin F20C,
unlike other natural prostaglandins, is a potent luteo¬
lytic agent in pseudopregnant rats. Given parenterally
in high doses this compound reduces the duration of
pseudopregnancy and lowers the level of progestogens
produced by the corpora lutea. It was soon confirmed
that this luteolytic effect is seen in many other
species under conditions where functional corpora lutea
are present - these included rabbit, guinea-pig, monkey,
cow, horse and pig (see Horton and Poyser, 1976).
In the last three, considerable veterinary application
has been made of this observation using both natural
prostaglandin F2Ct and synthetic analogues.
Considerable evidence had accumulated over the
years for the existence of a luteolytic hormone pro¬
duced by the uterus and acting upon the corpus luteum
within the ovary. All the evidence in guinea-pigs and
sheep tended to point to some local mechanism, the
hormone reaching its target via a vascular route other
than the systemic circulation. All attempts to isolate
and characterise luteolysin were foiled by the small
amounts of material available relative to the amounts
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required for assay during the purification procedure.
At the time of the discovery of the luteolytic action
of prostaglandin F2a, it was generally believed that
luteolysin was a peptide or protein.
Several procedures have been shown to stimulate
premature luteolysis, for example the presence of
beads in the lumen of the uterus and the injection of
oestrogen early in the cycle. There was also evidence
that these acted by releasing luteolytic hormone from
the uterus. This was the starting point for the
investigation in guinea-pigs described in part 3 of
the Experimental Section of this thesis. The historical
background and more recent developments have been the
subject of several reviews (Horton and Poyser, 1976;
Anderson, Bland and Melampey, 1969; Denamur and Netter,
1973; Rowson, 1970; McCracken, Carlson, Glew, Goding,
Baird, Green and Samuelsson, 1972; Pharriss, Tillson
and Erickson, 1972).
Nomenclature and Abbreviations
The basic 20-carbon skeleton of the prostaglandins
has been named prostane, the corresponding monocarboxylic
acid being prostanoic acid. The full chemical names of
all natural prostaglandins are derived by reference to
this basic skeleton. Since these full names are long
and tedious to use,trivial names have been retained for
most prostaglandins and these have been abbreviated fur¬
ther throughout the text of this thesis. The structural
formulae of the 2 series of prostaglandins showing
their route of derivation from arachidonic acid are
illustrated in Figure 1. Prostaglandins of the 1
series lack the 5,6-cis double bond whereas those of
the 3 series have an additional 17,18-cis double bond.
The full chemical names of the chief prostaglandins
dealt with in the study, together with the abbrevi¬
ations used in this thesis are given in Table 1.
Prostaglandin nomenclature was the subject of an
excellent paper by Nelson (1974).














ProstaglandinA, ProstaglandinB, ProstaglandinA2 ProstaglandinB2
pga, pgb, pga2 pgb9
15S-hydroxy-9-oxo-10,13-trans-prostadienoicaci 15S-hydroxy-9-oxo-8(12),13-trans-prostadienoicacid 15S-hvdroxy-9-oxo-5-cis-10,13-trans-prostatrienoica id 15S-hydroxy-9-oxo-5-cis-8(12),13-trans-prostatrienoicacid
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PROSTAGLANDINS FROM THE KIDNEY
A study of the output of Prostaglandins from the Rabbit
Kidney in vivo
Following the discovery that electrical stimulation
of the splenic nerve in the dog causes the release of
prostaglandin E2 into the splenic venous blood (Davies
et al, 1968), evidence accumulated in support of a
functional role for this prostaglandin as a modulator of
transmitter output at adrenergic nerve endings (see
Hedqvist, 1973). One criticism of this hypothesis is
that the various pieces of evidence supporting it have
been obtained in different species and/or organs
(Horton, 1973).
It was therefore decided to test the hypothesis in
three different ways using the same biological system.
The rabbit kidney was chosen because this organ is rich
in prostaglandins (Lee, Crowshaw, Takman, Attrep and
Gougoutas, 1967; Daniels, Hinman, Leach and Muirhead,
1967) and like the spleen has a rich and readily access¬
ible adrenergic innervation.
This study has shown that (1) renal nerve stimu¬
lation increases the output of prostaglandins into the
venous blood and that (2) indomethacin-induced blockade
of prostaglandin biosynthesis not only reduces or abol¬
ishes this release but also enhances the renal vasocon¬
strictor response to renal nerve stimulation. The third
piece of evidence was obtained by complementary experimental
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studies arranged with and carried out by colleagues in
Stockholm. They showed, also in the rabbit kidney,
that PGE2 infused intra-arterially reduces transmitter
output in response to electrical stimulation of the
renal nerve (Frame and Hedqvist, 1975).
METHODS
Surgical Procedures In each of six experiments, three
male litter-mate rabbits weighing between 1.5 and 3.0 kg
were used, two being blood donors for the third (experi¬
mental) animal. All animals were anaesthetized with
ethyl carbamate (urethane) in a dose of 1.75 g/kg
injected slowly as a 25% aqueous solution into a marginal
ear vein. The abdominal aorta of each donor rabbit in
turn was exposed and cannulated through a mid-line incision.
Heparin (1000 i.u./kg) was then injected intravenously and
blood was collected from the aortic cannula into poly¬
ethylene tubes.
The trachea, right external jugular vein, right com¬
mon carotid artery and right femoral vein of the experi¬
mental rabbit were then cannulated in that sequence.
Carotid arterial pressure was monitored throughout the
experiment with a Statham pressure transducer (P23DC)
and displayed on a Grass polygraph. A rectal thermometer
was inserted and the body temperature maintained at 37°.*
The abdomen was opened via a mid-line incision and
the left renal vein and nerve were exposed and dissected
free of connective tissue. Heparin (1000 i.u./kg body
weight) was then injected intravenously and the left renal
jlL,
Temperatures throughout are quoted in degrees
Centigrade
vein was cannulated. Renal venous blood was diverted
to the femoral vein via polyethylene tubing connecting
the renal and femoral cannulae. A Y-piece with a side-
arm was inserted for the collection of renal blood samples
this side-arm was clamped off between collections of
renal venous blood. Heparinized (donor) blood (10 ml)
was then slowly infused by a Watson-Marlow pump into the
right external jugular vein of the rabbit, in order to
compensate for the extra-corporeal blood in the renal-
femoral vein circuit. The renal nerve was cut 2 cm
from the kidney and wound around platinum electrodes
which were connected to a Grass stimulator (SD5). The
nerve and the kidney were bathed in a pool of liquid
paraffin.
All cannulae inserted into blood vessels in these
experiments were filled with a saline containing
heparin (50 i.u./ml), except for the carotid artery and
abdominal aorta cannulae, which were filled with a more
concentrated heparin solution (500 i.u./ml). After
surgery, a period of 30 minutes was allowed to elapse
before collecting blood samples.
Collection of Blood Samples The time periods for renal
venous blood sample collections and the volumes of the
samples are given in Table 2. During the collection of
all blood samples, the right femoral venous cannula was
clamped and the blood directed from the kidney into an
* 'saline' is used throughout the text to mean 0.9%
sodium chloride solution in distilled water
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ice-cold measuring cylinder. During the collection
of all samples, heparinized (donor) blood at 37° was
infused into the right external jugular vein. Blood was
infused at a slightly faster rate than it was being
removed. The blood pressure, therefore, remained fairly
constant.
A control sample of renal venous blood was initially
collected. This was followed by a 5 minute period during
which blood was directed from the renal vein into the
femoral vein.
In experiments 1 and 2 (Table 2), a test sample was
then collected. During this period, the renal nerve was
stimulated at 10 volts, frequency 10 Hz and duration
0.5 milliseconds. In experiment 2, the renal nerve was
stimulated for a further 20 minutes and a second test
sample (Test 2) was collected in the last 5 minutes of
this 20 minute stimulation period. A 20 minute interval
was then allowed during which renal venous blood was once
more directed into the femoral vein. This period allowed
time for the kidney to revert to 'pre-test' resting con¬
ditions before a final post-test sample was collected.
In experiments 3, 4, 5 and 6, the renal nerve was stimu¬
lated (as above) for 10 minutes before a test sample was
collected. A 15 minute period was then allowed during
which renal venous blood was directed into the femoral
vein.
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After collection of the test sample in experiment
3, 2 ml of polyethylene glycol 200 (Analar) and 1 ml of
saline were mixed and slowly injected into the right
external jugular vein. A 30 minute period was then
allowed before collecting a control polyethylene glycol
sample (Control Glycol). After collecting this sample,
the renal nerve was stimulated (as above) for 10 minutes,
before collecting a test polyethylene glycol sample
(Test Glycol). A 15 minute period was then allowed
during which renal venous blood was directed into the
femoral vein.
In experiment 3, after collection of the test
glycol sample, and in experiments 4, 5 and 6, after the
collection of the test sample, indomethacin (10 mg/kg)
dissolved in 2 ml of polyethylene glycol and 1 ml saline
was slowly injected into the right external jugular vein.
In experiment 4, a 10 minute period, but in experiments 3,
5 and 6, a 30 minute period was allowed before collecting
a control indomethacin sample (Control Ind.). After the
collection of this sample, the renal nerve was stimulated
for 10 minutes before collecting a test indomethacin
sample (Test Ind.).
In experiment 6 (Table 2), a 20 ml blood sample was
collected from the abdominal aorta before collection of
the initial renal venous control blood sample.
After collection of a blood sample, 0.1 p.Ci each of
(5,6-3Ha )-PGA1 , (5 ,6-3H2 )-PGE1 and (9-3H2 )-PGF2Ct was
added. This radioactivity represented 100 ng PGA,,
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150 ng PGE, and 3.3 ng PGF2a. Two volumes of saline
at 0° were then added to the blood samples. The samples
were kept at 0° until extraction.
TABLE 2
Experiment Samples Collection Volume of blood
number collected time (min) sample (ml)
1 Control 5 39
Test 5 30
2 Control 5 46
Test 1 5 49.5
Test 2 5 48
Post test 5 46
3 Control 4 55
Test 4 46
Control Glycol 4 42
Test Glycol 4 36
Control Ind. 4 40
Test Ind. 4 25
4 Control 7 41
Test 7 36.5
Control Ind. 7 26
Test Ind. 7 23
5 Control 7 33
Test 7 36
Control Ind. 7 41
Test Ind. 7 30
6 Control 5 50
Test 5 40
Control Ind. 5 22
Test Ind. 5 16
Samples collected before (Control) and during (Test)
renal nerve stimulation; after polyethylene glycol 200
and saline, samples collected before (Control Glycol)
and during (Test Glycol) nerve stimulation; after
indomethacin, samples collected before (Control Ind.)
and during (Test Ind.) nerve stimulation
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Extraction Procedure The diluted blood samples were
centrifuged for 10 minutes at lOOO g and 4°. The plasma/
saline was separated from the cells and stored at 0°,
while the cells were washed twice with an equal volume
of saline at 0°. The saline was removed from the cells
by centrifugation and added to the diluted plasma. The
pooled plasma/saline samples were adjusted to pH 4.5
with glacial acetic acid, then extracted by the methods
illustrated in Figure 2.
Silicic acid Column Chromatography Silicic acid, 4.5 g
(Sigma, Sil-R, 100 mesh) in 1 x 10 cm glass columns, was
activated by heating at 110° for one hour. After cooling
it was suspended in 10% ethyl acetate in toluene and
poured into the column. The dried residue from the solvent
extraction procedure was dissolved in 1 ml of 10% ethyl
acetate in toluene and applied to the column with a Pasteur
pipette. The residue flask was then washed with five
successive 2 ml portions of 10% ethyl acetate in toluene
and these separate washings were applied dropwise to the
column. Thus, 10 ml of the first 80 ml of 10% ethyl
acetate in toluene was used for transferring the extract
residue from the flask to the column.
The columns were run under reduced pressure at a
rate of approximately 1 ml/min. Prostaglandins were
eluted by stepwise increases in concentration of ethyl
acetate in toluene, namely, 10% (80 ml); 20% (80 ml);
40% (80 ml); 65% (150 ml); 80% (150 ml); 100% ethyl
acetate (80 ml); and finally methanol 100% (80 ml).
Plasma/saline pH4.5<- Petroleumspirit b.p.40-60°C (2x15ml)
Columnchro atography(Experiments1and2)
Ethylacetate (2x2volumes) I Washedwith10mlater I Evaporatedtdryness1 67%Ethanol (30ml) I Evaporatedtdryness Thin-layerchromatography(Experiments3,45and6)
Bioassay I
Combinedgaschromatography-massspectrometry
Figure2Proceduref rext actionofprostagla dinsfr mr nalve ouspl sma
to
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The order of elution of prostaglandins from the silicic
acid, as indicated by the radioactive tracer prosta¬
glandins, was as follows: PGAt in the 40% ethyl
acetate fraction, PGE, in the 65% and PGF2CC in the 80%.
Any PGC or PGB in the extract would co-chromatograph
with PGA,.
All eluates from the columns were evaporated to
dryness and re-dissolved in a known volume of methanol
for liquid scintillation counting. After this procedure
the samples were again evaporated to dryness. The 10%
and 20% eluate fractions were dissolved in 1 ml of 0.9
saline and two-fifths of the 40% fraction was dissolved
in 0.4 ml saline. These were assayed in terms of PGA2
on the kitten blood pressure preparation (Horton and
Jones, 1969). The remainder of the 40% eluate fraction
was analysed by combined gas liquid chromatography-mass
spectrometry (GLC/MS). The other eluates were dissolved
in 1 ml water for biological assay on the rat fundal strip.
These assay procedures were chosen because the rat
fundus is very sensitive to both PGE and PGF but relatively
insensitive to PGA and PGB whereas the kitten blood pres¬
sure is very sensitive to PGA (Horton and Jones, 1969)
and PGC (Jones, 1972), but less sensitive to PGB, PGE
and PGF. Since neither assay was sensitive to PGB com¬
pounds, these could only be detected by GLC/MS.
Thin-layer Chromatography Grooved glass plates
(Chromalay, May & Baker) of dimensions 20 x 5 cm were
used. The plates were coated with a 0.75 mm layer of
silica gel G (Merck). The silica gel, 30 g, was
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suspended in 57 ml of freshly re-distilled water for
spreading the plates. The plates were allowed to dry
overnight at room temperature and then used without
further activation. Each extract, containing tracer
PGA, , PGE, and PGF2CC was dissolved in 0.5 ml methanol
and applied, as a band, using an Agla micrometer syringe,
to the groove of the plate. The extract flask was washed
twice with 0.2 ml methanol and these aliquots were also
applied to the plate.
The plates were developed in the following solvent
system: toluene: dioxan: acetic acid (50:30:1) and a
16 cm run was used. All solvents were freshly re-distilled.
Using this solvent system, PGA, has an Rf value of about
0.5 whereas PGE and PGF have lower Rf values. This sol¬
vent system allows the plate to be developed twice without
prostaglandins of the A series running too far up the plate.
It does not, however, separate prostaglandins of the A, B
and C series. During the first 16 cm run, the prosta¬
glandins were eluted from the groove and thus separated
from pigments and more polar lipids which either remained
in the groove or very close to the origin. The tracer
prostaglandins were located on the plate by scanning with
a Panax thin-layer chromatogram scanner (RTLS-1A). The
silica gel in the groove and for approximately 1 cm
beyond the origin was scraped off, so as to leave a fur¬
ther 1 cm length of silica gel intact on the plate below
the start of the PGF zone. The plate was then developed
again in the same solvent system up to the 16 cm line.
The new locations of the tracer prostaglandins were
determined by scanning again. The zones of silica gel
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corresponding to the positions of the radioactive
tracers were scraped off and transferred to glass test
tubes which had been rinsed in methanol. The prosta¬
glandins were eluted from the silica gel with two portions
of 5 ml methanol. The methanol was evaporated to dryness
and the residues were re-dissolved in an accurately known
volume of methanol in preparation for liquid scintil¬
lation counting. All other silica gel zones on each
plate were also extracted and their radioactivity measured
to confirm that no prostaglandin had been left on other
parts of the plate.
After scintillation counting, the PGE, PGF and PGA
(C and B) eluates were evaporated to dryness. The PGE
andPGF residues were dissolved in water^ (1 ml) for bio-
assay on the rat fundus, whereas 40% of the PGA eluate
was dissolved in saline for bioassay on the kitten blood
pressure and 60% was retained for analysis by GLC/MS.
Liquid Scintillation Counting Radioactivity was
measured with a Nuclear Chicago Mark II liquid scintil¬
lation counter, using the channels ratio method. Samples
were dissolved in a known volume of either methanol or
or ethyl acetate. Aliquots (50 or 100 mcl) were pipetted
into vials to each of which was added scintillation fluid
of the following composition: toluene 2.5 1; 2,5-
diphenyoxazole (PPO) 10.65 g; 1,4-di-(2-(4-methyl-5-
phenyloxazolyl)-benzene ) 0.275 g. Counting efficiencies
for samples in organic solvents ranged between 40 and
50%.
'Water' throughout means glass distilled
unless otherwise stated.
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Further Purification of PGF Fractions After thin-layer
chromatography and biological assay, samples containing
PGF were purified further, prior to combined GLC/MS analysis.
To each sample in aqueous solution, 15 ml of pH 8.0 phosphate
buffer was added. The buffered extract was then extracted
by the method outlined in Figure 3. The pH 8.0 buffer was
prepared by adding 189.4 ml of 0.5M disodium phosphate to
5.3 ml of 1M sodium dihydrogen phosphate and making up to
1 litre with water.
Conversion of Prostaglandins of the A, C or E series to PGB
After biological assay, prostaglandins of the A, C or E series,
in the remainder of the extracts were converted to the corres¬
ponding PGB compound for identification by GLC/MS. The extracts
were evaporated to dryness and 1 ml of 0.1N KOH in methanol was
added. After one hour at room temperature (approximately 18°),
20 ml of water was added to each sample. This solution was
acidified to pH 4.0, using a pH meter, by the dropwise addition
of glacial acetic acid. It was then partitioned twice against
an equal volume of ethyl acetate. After separation the com¬
bined ethyl acetate phases were washed twice with 5 ml water
and then evaporated to dryness.
Gas Liquid Chromatography-Mass Spectrometry
The methyl ester/trimethylsilyl ether (Me/TMS), methyl
ester/trifluoroacetate (Me/TFA) and trimethylsilyl ester/
trimethylsilyl ether (TMS/TMS) derivatives were prepared
for combined GLC/MS on a micro-scale in 0.5 ml stoppered
test tubes, using the methods described by Thompson, Los
and Horton (1970).
pH8hosphatebuffer^^Ethylacet te (15ml)(2xl)I AdjustedtopH4 withaceticcid _.TT—EthvlacetatepH4<(2x30ml)
I
Washedwith2x5mlater Evaporatedtdryness Dissolvedinmethanolfor scintillationounting
Figure3Outlinofadditionalpurificationproceduref rPGFfr ct nsafter thin-layerchromatography
to
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Methyl esters were prepared by reacting the sample
with a freshly prepared solution of diazomethane in diethyl
ether-methanol (9:1) for 20 minutes. Trimethylsilyl ether
derivatives were formed by the addition of 13 pi of
bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) to the methyl
ester (Me/TMS) or the free acid (TMS/TMS) as the dry residue.
PGB derivatives required 15 minutes at 60° and PGF deriv¬
atives 3 hours at room temperature (approximately 18°) for
completion of the reaction. Without removal of the BSTFA,
approximately 12 pi were injected on to the gas chromato¬
graphic column. Trifluoroacetates were prepared by reacting
the methyl esters for 2 hours with 200 pi trifluoroacetic
anhydride which was then removed in a vacuum desiccator.
The Me/TFA derivatives were dissolved in 25 pi hexane and 10 pi
fractions (400 ng) were injected on to the GLC column.
Analyses were performed on an LKB 9000 gas liquid
chromatograph-mass spectrometer using methods previously des¬
cribed (Thompson et al., 1970; Davis, Horton, Jones and
Quilliam, 1971). The GLC column (1.5 metres long and 1.5 mm
internal diameter) was packed with 3% 0V1 on Supasorb AW
100-200 mesh pre-treated with dimethylchlorosilane in carbon
tetrachloride. Column temperature was either 2OO0 or 190°.
The carrier gas, helium, flowed at 20 ml/minute. All mass
spectra were recorded at an electron voltage of 27.5. Mass
spectra were recorded at the retention time corresponding
to the peak of the GLC peak of standard prostaglandins
similarly derivatized.
Biological Assays Smooth muscle preparations in vitro
were suspended in a 4 ml organ bath and longitudinal con¬
tractions were recorded isometrically with a force-displace¬
ment transducer (Grass FT.03) on a Servoscribe potentio-
metric pen recorder. A dose cycle of 4 to 7 minutes with a
contact time of 1 to 2 minutes was used for all preparations
All estimates of content were made by bracketting with pure
prostaglandins.
Rat fundal strip Fundal strips from rats weighing 100 -
300 g were prepared as described by Vane (1957) and sus¬
pended in Tyrode's solution vigorously gassed with oxygen
at 37°.
Rabbit .ie.junum Proximal jejunum from rabbits weighing 1
to 3 kg was suspended in Tyrode's solution gassed with air
at 37° (Horton and Main, 1965).
Kitten Blood Pressure Preparation Kittens weighing between
0.5 and 0.7 kg were anaesthetized with pentobarbitone sodium
(40 mg/kg) and the anaesthesia maintained with a slow inter¬
mittent intravenous pentobarbitone sodium infusion (5 mg/ml)
The blood pressure was recorded from a common carotid artery
using a Statham transducer and a Grass polygraph. Assay
samples were administered in saline by rapid intravenous
injection into the cannulated external jugular vein and
washed in with 0.2 ml saline (Horton and Jones, 1969).
27
Estimates of Recovery Recovery of the added tracer
prostaglandins after extraction and chromatography was
estimated by liquid scintillation counting. The following
recoveries were found: PGA, 55-89%; PGE, 42-70%;
PGF2a 60-90%. These radio-active recoveries for PGE,
and PGF2a agreed well with the recovery of added unlabelled
prostaglandins as estimated by bio-assay, namely PGE, (54-67%),
PGF2a (53-60%). However, recoveries of PGA, as measured by
bio-assay on the kitten blood pressure, namely 5-14%, were
far lower than those obtained by scintillation counting.
The recovery of PGA, from rabbit blood was therefore investi¬
gated further.
PGA, was added to four 40 ml samples of rabbit aortic
blood at 37°, containing heparin (20 i.u./ml), to give a
final concentration of 100 ng/ml in two samples and 200 ng/ml
in the other two samples. These concentrations of PGA,
included 5 ng/ml of tracer PGA, (0.2 pCi per sample).
The blood samples were extracted, as previously des¬
cribed. After thin layer chromatography, the material with
the chromatographic behaviour of tracer PGA, was eluted and
the percentage recovery estimated both by scintillation
counting and by assay on the kitten blood pressure. The
results (Table 3) suggest that PGA, is at least partly
converted to a biologically inactive product during the
extraction procedure.
After bioassay, the Me/TMS derivatives of the remaining
prostaglandin-1ike material in the extracts of the four
samples was prepared for GLC/MS. Mass spectra taken at the
TABLE3
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retention times of pure PGA, (7.9 minutes) and PGB, (11.9
minutes), confirmed that the extracts of all samples con¬
tained PGB, but only extract No. 1 contained any PGA,. Since
the final extracts still contained many other substances,
quantitation by GLC/MS was not possible and the percentage of
PGA, converted to PGB, could not be calculated by this method.
Since PGA, is very rapidly converted enzymatically to
PGC, in the presence of rabbit blood even at 0P (Jones, 1970)
and since PGC, is then isomerized non-enzymatically but more
slowly in aqueous solution to PGB, (Jones, 1972), it is prob¬
able that PGC, was also present in these blood extracts.
Since PGC, is active in lowering kitten blood pressure (Jones,
1972) but would not be detected (except possibly as PGB,)
on GLC/MS, the possibility of such enzymatic loss of PGA,
could explain the discrepancy in the results. The liquid
scintillation counting procedure would not distinguish
between radioactivity present in PGA,, PGB, or PGC,.
RESULTS
Output of prostaglandins into renal venous blood
Prostaglandins E2 and F2a were detected in renal venous
blood samples of all six experimental rabbits under resting
conditions. When the renal nerve was stimulated electrically,
this output increased in all cases (Table 4). There was a
less consistent and less pronounced increase in the output of
a PGA compound also.
Intravenously injected indomethacin in four experiments
reduced the resting output in response to renal nerve
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stimulation. Injection of the solvent vehicle alone
(polyethylene glycol 200 and saline) did not abolish nerve-
stimulated output.
Identification of prostaglandins in renal venous blood
In every experiment prostaglandins were identified on
the basis of GLC/MS supported by their partition, chromato¬
graphic and biological properties. The results obtained in
one experiment (No. 3) are presented in detail below; similar
results were obtained in the other experiments.
Identification of PGF2a
In experiment 3 (Table 4) the material in control and
test samples with chromatographic behaviour corresponding to
PGF2a was assayed biologically on the rat fundus. After
phosphate buffer partition, each sample was divided into two
parts for the preparation of Me/TMS and Me/TFA derivatives
prior to GLC/MS.
Mass spectra taken at the appropriate retention times
showed that both control and test samples contained PGF2a.
PGFia could not be detected. The mass spectral data
(m/e peaks greater than 300) are shown in Figure 4. The
small amounts of tracer (3.3 ng) added could not have been
detected by the GLC/MS method.
The Me/TMS derivative of pure PGF2a had prominent
mass spectral peaks at 584 [m+], 569 [m - 15], 513 [m - 7l],
494 [m - 9o] , 423 [m - (90 + 71)], 404 [m - (2 x 90)],
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Figure 4 Mass spectra of the Me/TMS derivatives of
standard PGF2Ct (upper) and of half the PGF
fraction from the test sample in experiment 3
(lower)- material extracted from renal
venous blood collected during renal nerve
stimulation
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379 [M - (114 + 90 + 1)] , 353 [M - (141 + 90)] ,
333 [m - (2 x 90 + 71)], 314 [m - (3 x 90)]and 307. The
presence of these 11 peaks in approximately the same ratios
in the mass spectra of both the control and test extracts
confirmed that the PGF-like material detected by bioassay
was PGF2a.
Further confirmation was obtained with the Me/TFA
derivatives. That of authentic PGF2a showed prominent peaks
at 542 [m - 114], 511 [m - (31 + 114)], 441 [m - (101 + 114)],
428 [m - (2 x 114)] and 314 [m - (3 x 114)]. The same five
m/e peaks in similar ratios were present in both control and
test samples (Fig. 5).
Identification of PGE2 Material from both control and test
samples with the chromatographic behaviour of PGE2 contracted
the isolated rat fundus.
After conversion to PGB2 and derivatization to Me/TMS,
authentic PGE2 showed prominent mass spectral peaks identical
to the Me/TMS of authentic PGB2 , namely: 420 [m + ], 405 [m -» 15],
389 [m - 3l], 349 [m - 7l], 330 [m - 9o], 321 [m - (71 + 28)],
279 [m - 14l], 247 [m - 173], 221 [m - 199] and 199. These
characteristic peaks were also found in the control and test
samples similarly derivatized, the mass spectra being taken
at 8.9 minutes corresponding to the retention time of authen¬
tic PGB2, Me/TMS. PGB,, Me/TMS had the same retention time
but m/e peaks corresponding to this compound (2 a.m.u. greater
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Figure 5 Mass spectra of the Me/TFA derivatives of
standard PGF2a (upper) and of half the PGF
fraction from the test sample in experiment 3
(lower) - material extracted from renal
venous blood collected during renal nerve
stimulation
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Figure 6 Mass spectra of the Me/TMS derivatives of
standard PGB2 (upper) and of the PGE fraction
(after conversion to PGB) from the test sample
in experiment 3 (lower) - material extracted
from renal venous blood collected during
renal nerve stimulation
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This evidence confirmed that the original extracts
contained predominantly PGE2 not PGE,. In other instances
the TMS/TMS derivatives were prepared and again the results
indicated the presence of PGE2 but no (or negligible) PGE,.
Identification of PGA2
Material which co-chromatographed with tritiated PGA,
in both control and test samples of experiment 3, lowered
the kitten blood pressure on intravenous injection. This
effect could have been due to a PGA, to smaller quantities
of the corresponding PGC, to very high amounts of PGB or
to a mixture (Table 5).
The Me/TMS derivatives of PGB2 and PGB, both had a
GLC retention time of 10.0 minutes. Neither test nor
control samples contained any detectable amounts of
either of these prostaglandins. However, the amount of
PGA or PGC present calculated from the bioassay results
would not yield sufficient PGB to be detected by the
GLC/MS method used. Only if the biological activity in
the sample had been wholly or largely attributable to the
presence of a PGB, would this compound have been readily
detected by GLC/MS. Since it was not, the original
compound present in the extracts must have been a PGA
or a PGC or both, the concentration being low.
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TABLE 5 Amounts (ng) of PGA-like activity assayed
on the kitten blood pressure in control and
test samples (experiment 3) expressed in








The effect of polyethylene glycol 200 on prostaglandin output
In experiment 3, following the injection of a mixture of
2 ml of polyethylene glycol 200 and 1 ml saline intravenously,
systolic blood pressure rose by 22 mm Hg and diastolic by
12 mm Hg. This effect lasted 10 minutes. Although there
was a fall in output of prostaglandin of all three series
following glycol injection, the resting output of prostaglandins
was not abolished nor was their release in response to nerve
stimulation prevented (Table 4). Both PGE2 and PGF2Ct were
identified by GLC/MS in control and test samples of experi¬
ment 3 following polyethylene glycol administration.
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The effect of indomethacin on prostaglandin output
Following the intravenous injection of indomethacin,
systolic blood pressure rose by 10 to 40 mm Hg and dia¬
stolic by 16 to 28 mm Hg. These effects lasted longer
than an hour in all four experiments (3, 4, 5 and 6).
In experiments 4 and 6 total renal blood flow also decreased.
Indomethacin reduced the resting output of renal venous
PGE2 and PGF2a in all four experiments and virtually abol¬
ished the release of prostaglandins in response to renal
nerve stimulation (Table 4). The resting levels were
lowered 10 minutes after indomethacin (experiment 4) but
greatly lowered 30 minutes after indomethacin (experiments
3, 5 and 6). Therefore only in experiment 4 was sufficient
PGE2 and PGF2a released spontaneously after indomethacin
to be identified by GLC/MS. By pooling resting samples
from the three other experiments collected 30 minutes
after indomethacin, the total amount of PGF2a present was
just sufficient to be identified by GLC/MS. PGE2, however,
could not be detected by GLC/MS in these pooled post-
indomethacin samples.
Concentrations of prostaglandins in arterial blood
In experiment 6, a 20 ml aortic blood sample was col¬
lected before the first control sample of renal venous
blood. The levels of PGA (< 2 ng/ml PGA, equivalent) and
PGF (<3.5 ng/ml PGF2a equivalent) were undetectable by the
methods used above. However, a low concentration of PGE2
(about 1.5 ng/ml) was detected by bioassay on the rat
fundus. The identification of this arterial PGE2 rests
upon its chromatographic behaviour and its biological
activity - there was insufficient material for GLC/MS.
It is apparent, therefore, that the amounts of prosta¬
glandins of all three series found in renal venous blood
in the absence of nerve stimulation greatly exceed those
present in the arterial blood supplying the kidney. In
experiment 6 under resting conditions, the concentration
of PGE2 in the renal vein was more than 30 times that
found in the renal artery. In other rabbits not used
in these experiments the arterial levels of prostaglandins
were almost invariably below the limits of detection.
DISCUSSION
In all six experiments PGE2 , PGF2CC and a PGA- like
compound were found in renal venous blood collected under
resting conditions. The amounts exceeded those found in
arterial blood; hence it may be concluded that the
prostaglandins found in renal venous blood are of renal
origin; they appear to be released 'spontaneously'. In
all instances their output was increased by stimulating
the renal nerve electrically and in all instances the PGE2
and PGF2a have been identified by their GLC/MS behaviour
in addition to their biological, chromatographic and par¬
tition properties.
The precise nature of the PGA- like material remains
in doubt. Moreover, if it was PGA2 (or its product PGC2 )
it could have arisen from PGE2 artefactually during the
extraction procedure (Lee ejt al. , 1967). It is known
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that the use of an organic acid in preference to a mineral
acid during the extraction procedure reduces the likeli¬
hood of dehydration of PGE2 (Andersen, 1969). Acetic acid
was used in this investigation for acidification of extracts,
furthermore the acid was always removed by washing with water
as quickly as possible during the separative procedure.
This should have minimized the amount of chemical degrad¬
ation of PGE2 but other techniques would be needed to
exclude this possibility altogether.
Handling of organs may cause prostaglandin release
(Piper and Vane, 1971) but in this study the kidney was
not touched and 30 minutes was allowed after the surgical
procedure was completed before collecting blood samples.
It seems unlikely, therefore, that the 'spontaneous'
release could be attributed to manipulation of renal
tissue.
Both PGE2 and PGF2Ct output increased during nerve
stimulation in all experiments. This confirms previous
findings in the dog spleen (Davies et al^. , 1968) where
adrenergic nerve stimulation also increases the output of
both these prostaglandins. However the dog spleen does
not release detectable amounts of prostaglandins in the
absence of stimulation, despite much greater inevitable
manipulation and handling during the surgical procedures
than in the present study.
In all four experiments in which the effect of
indomethacin was tested, spontaneous release of prosta¬
glandins was reduced by the drug whilst the increased out¬
put in response to nerve stimulation was abolished.
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Moreover, this abolition of prostaglandin output was
accompanied by significant physiological changes, the
arterial blood pressure was raised and renal blood flow
reduced. These changes are compatible with the postu¬
lated role for prostaglandins at adrenergic nerve endings
reducing transmitter output in response to nerve stimu¬
lation .
Frame and Hedqvist (1975) also working on the rabbit
kidney have shown that the intra-arterial infusion of PGE2
reduces the output of noradrenaline in response to nerve
stimulation. This evidence taken with the findings here
that PGE2 is released from the kidney on nerve stimulation
and that blockade of its synthesis leads to vascular changes
typical of enhanced sympathetic nerve activity strongly
suggests that PGE2 does have a role at adrenergic nerve
endings in the kidney as a modulator of transmitter out¬
put. Support for the hypothesis originally formulated by
Hedqvist (1971 ) is stronger from this study than from
previous investigations because all the observations have
been made on the same preparation. Moreover, the nature
of the prostaglandins released is based in this study on
far less equivocal data obtained by mass spectrometric
analysis.
What the hypothesis in its present form does not
account for is the release of other prostaglandins, notably
PGF2Ct and the PGA-like compound. There is currently no
convincing evidence to suggest that these prostaglandins
have a physiological role at adrenergic nerve terminals,
although it is claimed that PGF2a may enhance transmitter
release (Kadowitz, 1972). However, the concommitant
release of several prostaglandins does not itself negate
the evidence regarding a role for PGE2, though it may
mean that the hypothesis will need modification in the
light of future results.
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PROSTAGLANDINS FROM THE MALE REPRODUCTIVE TRACT
A Study of the Daily Output of Prostaglandins in Human Semen
and the Effects of Treatment with High Doses of Aspirin
Human semen contains several different prostaglandins and
is the richest known vertebrate souce of these substances.
Inhibition of the biosynthesis of prostaglandins by aspirin
was discovered in 1971 (Ferreira et <rl. , 1971; Smith and
Willis, 1971; Vane, 1971); subsequently Collier and Flower
(1971) reported that male volunteers treated with aspirin
had reduced seminal levels of prostaglandins as measured by
biological assay in terms of PGE2 and PGF2Ct.
The object of the present investigation was to determine
how completely prostaglandin synthesis in man can be inhib¬
ited by high doses of aspirin (3.6 and 7.2 g/day). The prosta¬
glandins were measured by physico-chemical methods and bioassay,
estimates of recoveries being obtained by the use of a radio¬
active tracer. Fructose levels were also measured.
METHODS
Human Subjects Two healthy adult males aged 25 (subject A)
and 42 (subject B) each collected ejaculates manually between
0800 and 0900 hours every 24 hours, each over two periods of
9 to 12 days. The first sample in each series was discarded.
After 2 to 5 control collections aspirin (soluble aspirin
tablets B.P.) was taken orally in divided doses for 3 days.
Dose levels of 3.6 and 7.2 g/day were studied in each subject.
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Extraction of Prostaglandins Seminal fluid was collected
into a tared flask containing 0.2 pCi 5,6-3H-PGE1 (specific
activity 210 Ci/mol ) in 2 ml saline. The flask was re-weighed
immediately following collection and stored at 4° for up to
one hour. Saline (20 ml) was then added and the diluted
ejaculate was centrifuged at 1200 g for 5 minutes. The
supernatant was poured off, the pellet re-suspended in a
further 20 ml saline and the centrifugation repeated. The
combined supernatants were made up to 50 ml with saline and
5 ml of this was removed to a separate vessel and stored
at -20° for fructose assay. The remainder of the sample
was acidified to pH 4 with 10% citric acid solution and
extracted twice with 2 volumes of diethyl ether. The com¬
bined ether phases were washed with 20 ml water and then
concentrated in vacuo to about 20 ml. The concentrate
was extracted twice with equal volumes of 0.1 M tris-HCl
buffer (pH 9.0). The combined buffer phases were acidified
to pH 4 and extracted twice with equal volumes of diethyl
ether. The combined ether phases were washed with 5 ml
water and evaporated to dryness.
The residue was dissolved in a small volume of toluene:
methanol (1:1) and applied to a previously prepared silica
gel chromatography plate (Merck). The plate was developed
to a height of 15 cm in the A VII solvent system of Hamberg
and Samuelsson (1966). The zone containing the labelled PGEt
was detected with a Panax thin layer chromatogram scanner
(RTLS - 1A). The silica gel from two zones, one containing
the prostaglandins E (Rf 0.31 to 0.44) and the other the
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prostaglandins F and the 19-hydroxy-prostaglandins (as
A and B) (Rf 0.16 to 0.31) was removed from the plate.
The prostaglandins were eluted from the silica with methanol.
Estimation of Prostaglandins Spectroscopic assays of the
prostaglandins were performed with a Pye Unicam SP800
ultra-violet spectrophotometer. After appropriate dilution,
2 ml of the chromatogram eluate were placed in a cell of
10 mm path length and a spectrum was recorded between 250
and 325 nm. N-potassium hydroxide in methanol (0.2 ml)
was added to the cell and the spectra were recorded at 5
minute intervals until the extinction change at 278 nm had
reached a maximum. TheF for the conversion of PGE,
2 7 8 1
to PGB, is 27,200 (Andersen, 1969).
Gas chromatographic-mass spectrometric analysis of
the methyl ester-trimethylsilyl ether derivatives of the
prostaglandins B was carried out by the method of Thompson
et al^.,(l970). The amount of radioactivity in the PGE
eluates was determined with a Nuclear-Chicago Mk II liquid
scintillation counter. The prostaglandin F eluates were
assayed biologically in terms of PGF2a on the isolated
rabbit jejunum (Horton and Main, 1965).
Estimation of Fructose The fructose content of the seminal
fluid was measured using the resorcinol/HCl reaction as
described by Mann (1948). The extinction of the chromophore
at 400 nm was measured spectrophotometrically. Glucose-free
D (- )-fructose (B.D.H.) was used to produce a calibration
curve.
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Statistical Analysis For statistical analysis by Student's
t test, the mean of all pre-treatment and the second and
third post-treatment values (mean controls) was compared
with the mean of the second and third treatment values
(mean test).
RESULTS
Weight of ejaculates collected by 24 hour intervals
In both subjects there were daily fluctuations in the
weight of ejaculates but no obvious trend could be detected
in these variations over the 8 to 11 day periods of the
study (Tables 6 and 7). The weights of the ejaculates
collected during aspirin treatment at the two dose levels
were not significantly different (P >0.1) from those
collected during the control periods in four experiments
(two in each subject) (Table 8).
Seminal fructose
In subject A, the mean fructose levels during the
control periods and during the aspirin (7.2 g/day) adminis¬
tration were 2.32 and 2.50 mg/g respectively. The difference
was not statistically significant (P >0.1). The levels in
subject B were lower, 1.06 and 1.38 mg/g during the control
periods and 1.31 and 1.30 mg/g during the treatment with
low and high dosage of aspirin. These differences were also
not significant (Table 8).
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Prostaglandins E
By converting PGE compounds to their PGB derivatives
and measuring the resultant absorption at 278 nm, an esti¬
mate of total PGE is obtained. This method does not provide
a separate estimate of PGE! and PGE2. In one experiment,
the PGB formed by this method in a control sample showed
a single peak as its methyl ester-trimethylsilyl ether
derivative on gas chromatography at a retention time cor¬
responding to that found for authentic PGB, (which does
not separate from PGB2 on the gas chromatographic system
used). A mass spectrum taken during the GLC peak exhibited
prominent m/e peaks in pairs at a.m.u. values of 422 and
420 [M+], 391 and 389 [m - 3l] , 351 and 349 [m - 71 ] , and
323 and 321 [m - (71 + 28)] . This corresponds to a mixture
of PGB, and PGB2 (see Fig. 6), the heights of the pairs
of peaks differing by 2 a.m.u. indicating approximately
equal amounts of PGE, and PGE2 in the original sample.
The mean recovery determined by the tritium-labelled inter¬
nal standard was 42% (+_ 12). Concentrations of PGE shown,
in the Tables are corrected for recovery.
The levels of PGE fluctuated during the control period
but no obvious trend in these variations could be detected.
During treatment with aspirin in both subjects, the levels
of PGE fell by 52% and 60% at the 3.6 g/day level and by
78% and 82% at the 7.2 g/day level. The effect was maximal
after 48 hours of treatment, but after 72 hours of treatment
the PGE levels were slightly but consistently higher in all
four experiments. A return to pre-treatment levels of
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PGE had occurred by 48 hours after cessation of aspirin
treatment.
19-Hydroxy-prostaglandins
In both subjects, ejaculates collected at 24 hour
intervals contained far lower concentrations of the 19-
hydroxy-prostaglandins than of PGE. The levels of these
19-hydroxy compounds (estimated in terms of 19-hydroxy-PGB)
were not corrected for recovery since there was no available
source of isotopically-labelled internal standard. The
levels of the 19-hydroxy compounds fell to a minimum after
48 hours of aspirin treatment, but then started to rise
despite continued treatment.
Prostaglandins F
In ejaculates collected at 24 hour intervals, the
levels of PGF were low as measured biologically on the
isolated rabbit jejunum after thin layer chromatography
and after treatment of the sample with dilute KOH (which
does not inactivate PGF). There was a difference between
the two subjects. Subject A had a control level equivalent
to 2.9 g PGF2a/g semen which fell to 0.21 g/g during treat¬
ment with aspirin at 7.2 g/day, whereas subject B had less
than 0.5 [ig/g even during the control periods and the
contractions were qualitatively different from those to
PGF2a. Contractions of the jejunum to the extract were
quick in onset and short-lived whereas those to PGF2a were
more gradual in onset and longer-lasting. The nature of this
substance was not. determined but its presence made estimates
of PGF levels in subject B unreliable.



























































































































Symptoms experienced during aspirin treatment
At the lower dose level of aspirin (3.6 g/day), no
side effects were reported by either subject. At 7.2 g/day,
subject A experienced tinnitus, deafness and slight hyper-
pnoea 24 hours after the start of treatment. After 48 hours
the symptoms were most marked. There was nausea but no
vomiting and the faeces were dark in colour. In view of
the possibility of a severe gastro-intestinal haemorrhage,
aspirin treatment in this subject was stopped after 64 hours.
The severe symptoms persisted for a further 20 hours, were
slight after 56 hours and were absent 80 hours after the
cessation of aspirin therapy.
At the higher dose level, subject B reported trouble¬
some tinnitus and deafness throughout the treatment period,
but the treatment was not curtailed. These symptoms were
still marked 16 hours after the end of the treatment.
Abdominal discomfort, heartburn and epistaxis occurred
during the last day of treatment.
DISCUSSION
In a previous investigation, Collier and Flower (1971)
showed that human seminal prostaglandin levels, estimated
by bioassay, are reduced during a 7-day course of aspirin
treatment (2.4 g/day). In the present investigation both
PGE and 19-hydroxy-prostaglandin, which together comprise
about 90% of the total prostaglandin content of human semen,
have been measured using an absorptiometric method
(Bygdeman and Samuelsson, 1966) which is more accurate than
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bioassay. The use of a radioactive internal standard
enabled corrections for recoveries to be made (with
respect to PGE).
With these physico-chemical methods of determination,
it has been possible to show that aspirin administration
reduces the levels of the three groups of prostaglandins
in human semen. However, even at near toxic doses used
in this study, the PGE content was never reduced to zero,
although 19-hydroxy prostaglandin levels became undetect¬
able and the PGF levels were reduced by over 90% in one
subject. On the other hand, this effect of aspirin appears
to be selective since neither the quantity of semen nor the
fructose levels were affected even by the higher dose.
The results provide evidence that in human subjects,
aspirin in high therapeutic doses reduces the levels of
all prostaglandins in the semen. If seminal prostaglandins
are important for fertility, these drug-induced low levels
may be associated with diminished fertility. It seems
unlikely, in the light of toxic effects experienced by
both subjects, that high aspirin dosage could be maintained
for sufficiently long periods in man to put this suggestion
to the test. It is possible that a retrospective study
amongst male patients on a high aspirin regime therapeuti¬
cally might reveal some interference with fertility, but no
evidence has so far been produced.
It is not clear whether prostaglandins of the E series
or their hydroxylated derivatives (Kelly and Taylor, 1976)
are likely to be the more important physiological constituents
of human semen. Both are present in exceptionally high
concentrations though in certain primates it is the
19-hydroxylated derivatives only that are found. The
biosynthetic route of the 19-hydroxy compounds is not
known but this study showed that their production is
reduced by aspirin and therefore that they are likely
to be indirect products of the enzyme, fatty acid
cyclo-oxygenase.
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PROSTAGLANDINS FROM THE FEMALE REPRODUCTIVE TRACT
A Study of the Output of Prostaglandins by the
Guinea-Pig Uterus under Various Conditions and the
Role of Prostaglandin F2a as the Uterine Luteolytic Hormone
Hysterectomy in the guinea-pig is followed by great length¬
ening of the oestrous cycle (Loeb, 1923). This is a local
effect since removal of only one horn results in ipsilateral
retention of functional corpora lutea. Work on both guinea-
pigs and sheep prior to 1970 provided much evidence to support
the hypothesis that the uterus in these species secretes a
substance which is luteolytic (Anderson et al., 1969)
Premature luteolysis can be induced by inserting beads
into the uterine lumen of guinea-pigs (Donovan and Traczyk,
1962) or by administration of oestrogen early in the
cycle (Bland and Donovan, 1970). These two stimuli appear
to exert their luteolytic effects by causing premature
release of the luteolytic hormone, and were used as the
starting point in this study which concerned the identifi¬
cation of the luteolytic hormone. The reports of the
luteolytic activity of PGF2C£ by Pharriss and Wyngarden (1969)
and Blatchley and Donovan (1969) considerably simplified
this task since the question which then had to be answered
was: 'Is the luteolytic hormone in the guinea-pig identical
with PGF2(X?' .
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The truth of this hypothesis has been subjected to
various kinds of test reported here. It appears that the
guinea-pig does release PGF2(X from its uterus under physio¬
logical conditions and this contributes to the control of
oestrous cycle length.
METHODS
Distension of guinea-pig uterus in vitro Female guinea-pigs
weighing about 500 g were smeared daily by a vaginal lavage
technique and killed on day 3 or 4 of the oestrous cycle
(day 1 being the day before the post-ovulatory influx of
leucocytes, when cornification of the vagina was maximal).
The two uterine horns were removed and separated. One
horn was distended by the intraluminal insertion of a piece
of polyethylene tubing (3 mm wide and 30 mm long). The
other horn was treated similarly except that the polyethylene
tubing was removed immediately after insertion. Both horns
were incubated separately at 37° in 8 ml of Tyrode's solution
for 3 hours and gassed with 5% C02 in oxygen. The two
incubated solutions were assayed on the rat fundal strip
(see p. 26) in terms of PGE, and of PGF2Ct.
The pooled test and control samples were then extracted
by the procedure outlined in Figure 2 (p. 19) and re-assayed
in terms of prostaglandins.
Silicic acid column chromatography, formation of Me/TMS
and Me/TFA derivatives and combined GLC/MS were performed as
described previously (p. 23 and 25).
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Effect of oestrogen treatment Guinea-pigs were injected
subcutaneously with 10 jig of oestradiol benzoate (Oestroform,
British Drug Houses) on days 4, 5 and 6 of the oestrous
cycle. Blood was collected from them on day 7. Groups of
5 animals were injected and the same number of untreated
day 7 guinea-pigs were used as controls. Plasma from
4 or 5 treated guinea-pigs was pooled in each experiment
to give approximately 30 ml. Plasma from untreated con¬
trols was similarly pooled. This comparison was made in
eight separate experiments.
Investigation of guinea-pigs during the oestrous cycle
Adult female guinea-pigs of mixed stock weighing 500 to 800 g
were used. They were housed under constant conditions of
light and temperature, fed a proprietary diet (RGP, Dixon 8t
Sons Ltd, Ware) and given drinking water to which ascorbic
acid (lg/l) and citric acid (2 g/1) were added as an anti¬
scorbutic measure, ad libitum.
Blood collection Animals were anaesthetized with pento¬
barbitone sodium (Nembutal, Abbott Laboratories Ltd)
400 mg/kg injected intraperitoneally. A large ventral mid¬
line abdominal incision was made and the alimentary tract
was displaced and kept damp in a polyethylene bag. The
utero-ovarian vein on one side (usually the left) was exposed,
care being taken to avoid manipulation of the uterus, and
the fat surrounding the vein was handled as little as poss¬
ible. The vein can be very small and frail and constricts
to a mere thread unless great care is taken. For this
reason no attempt was made to separate the artery and the
vein which are very closely applied to each other. After
placing a ligature round the vein as far cranially as pos¬
sible, 5000 i.u. heparin (Pularin, Evans Medical Ltd) were
injected into a vein in the leg. The ligature round the
utero-ovarian vein was tightened and a needle attached to
a silastic tubing (internal diameter 0.025 in., external
diameter 0.047 in.) was inserted into the vein with the
aid of a dissecting microscope. Blood was allowed to
flow under negative pressure into an ice-cooled tube for
60 to 90 minutes before the animal was killed, by which
time about 10 to 16 ml had been collected. Oestrogen
pre-treatment did not appear to alter the volume of blood
collected during this period. When the collection was
finished and a haematocrit taken, the blood was centrifuged
at 4° and the plasma stored at -20° until extracted and
assayed.
Schedule of blood collection from cyclic guinea-pigs Blood
was collected from 5 animals each on days 3, 9, 10, 11, 12,
13, 14 and 15 of the cycle. A small aliquot of plasma from
each guinea-pig was kept for progesterone analysis, the
remainder being pooled for each of the groups so that 30
to 40 ml plasma per day was available for prostaglandin
analysis.
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Estimation of progesterone levels by protein binding
0.1 ml plasma from the utero-ovarian vein was diluted 15
times with water and 0.1 ml of the diluted solution assayed
by a rapid competitive protein binding method based on that
described by Johansson (1969). Progesterone was extracted
by shaking with 2.5 ml petroleum ether (Mallinckrodt 4980,
b.p. 30-50° Lot XKH) for one minute. The petroleum extract
was dried and the protein binding reaction carried out using
corticosteroid-binding globulin (obtained on day 21 of the
menstrual cycle from a human volunteer who was regularly
taking a combined oestrogen-progestogen contraceptive pill)
labelled with (3H)-corticosterone (31.7 Ci/mmol, Radio¬
chemical Centre, Amersham). The progesterone extracted
from the samples displaced the labelled corticosterone
in proportion to the amount of progesterone present. A
standard curve was run in parallel. After separation of
the free and bound steroid by the use of the adsorbent
Florisil (VMA Purifier, Sigma), 0.5 ml aliquots were added
to scintillation fluid and counted with an efficiency for
tritium of 40%. Samples were assayed in duplicate on
two separate occasions and if the mean value of each assay
differed by more than 10%, a third assay was carried out.
The coefficient of variation in the measurement range of
0.0 to 2.0 ng on the standard curve was less than 15%.
The mean percentage recovery of (3H)-progesterone from the
plasma samples over a three-month period was 91.5 + 0.8%.
The method measured total progestins but the contribution
from 17a-hydroxy-progesterone was limited by its low
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extraction from plasma (30%) whilst contribution from
20a-dihydroprogesterone was reduced by its low affinity
to corticosteroid-binding protein. Moreover, it has been
reported that insignificant amounts of these two substances
are produced by the guinea-pig (Challis, Heap and Illingworth,
1971). Known amounts of progesterone added to plasma from
castrated male guinea-pigs were almost wholly recovered
over the range 0.0 to 5.0 ng progesterone. The limit of
sensitivity of the method when measuring progesterone in
utero-ovarian venous plasma is 12 ng/ml plasma.
Estimation of progesterone by radioimmunoassay Blood (2 ml)
was collected by cardiac puncture from guinea-pigs treated
with indomethacin or actively immunized or control animals
three times weekly (Monday, Wednesday and Friday) throughout
the investigation. The animals stood up well to this regime
and remained healthy. Eventually they died of pericardial
haemorrhage following cardiac puncture. The blood was
drawn into a syringe containing 10 i.u. heparin in 0.1 ml
saline. The plasma was separated by centrifugation and
stored at -20° until assayed. Progesterone levels were
determined by radioimmunoassay. The antibody which had
the cross-reactivities shown in Table 9, was kindly supplied
by Drs Dighe and Hunter whose method of assay was followed
(Dighe and Hunter, 1974), 0.2 ml of each plasma sample
being extracted in duplicate by light petroleum (b.p. 40-60°).
Recoveries of progesterone were determined by their method
alone. Tritiated progesterone (specific activity 81 Ci/mmol)
TABLE 9 Cross-reactivity of progesterone antiserum
as determined by K. K. Dighe using the
































was supplied by the Radiochemical Centre, Amersham.
The accuracy and precision of the assay were determined
by adding known amounts of progesterone to 0.2 ml male
guinea-pig plasma and estimating the amount recovered.
For quality control purposes, 0.1 or 0.2 ml of pooled
plasma from guinea-pigs in the luteal phase was incorpor¬
ated into each assay. From the results obtained the co¬
efficient of variation between assays was calculated. The
coefficient of variation within assays was calculated by
the method of Dighe and Hunter (1974).
Estimation of prostaglandin levels Prostaglandins were
extracted from plasma, separated by silicic acid chromato¬
graphy, bioassayed on the rat fundal strip and analysed by
GLC/MS using methods described above (pp. 18-25).
Prostaglandin recovery experiments The percentage recov¬
eries of PGF2Ct and PGE2 over concentration ranges from
10 ng/ml blood upwards were estimated as follows. Blood
was collected from three guinea-pigs and heparinized.
Sufficient prostaglandin was added to give the required con¬
centration and after mixing, the blood was incubated at 37°
for 1 hour before centrifugation. The plasma samples were
extracted, chromatographed and bioassayed as described above.
The percentage recoveries thus calculated were for PGF2Ct
(10, 20 and 330 ng/ml) 48, 44 and 45% respectively and for
PGE2 (10, 30 and 50 ng/ml) 43, 46 and 48% respectively.
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Derivatization of prostaglandin E The sample was first
esterified with diazomethane as described above (p. 25).
The methoxime was then prepared by the addition of 150 Ul
of a freshly prepared solution of 1% methoxyamine hydro¬
chloride in pyridine. After 12 hours, the sample was
evaporated to dryness i_n vacuo, and the TMS formed by the
addition of 25 Ul BSTFA. On GLC two peaks were obtained
corresponding to the two stereoisomers of the methoximes.
In other experiments PGE was first converted to PGB
(as described above, p. 23). The PGB was purified by solvent
extraction and thin layer chromatography in the toluene:
dioxan:acetic acid system already described. The Me/TMS
derivative of this purified PGB was then prepared for GLC/MS.
Derivatization of prostaglandin F Me/TMS and Me/TFA deriv¬
atives were prepared as above (p.25 ).
Indomethacin Injections Indomethacin dissolved in 0.5 ml
polyethylene glycol was injected subcutaneously at 12 hourly
intervals from the 7th day of the cycle until the 1st day of
the next cycle, at two dose levels (4 and 20 mg/day).
Control guinea-pigs were similarly injected with 0.5 ml
polyethylene glycol.
Intra-uterine implants of indomethacin Implants (15 mm
long, 2 mm maximum diameter, weighing 25 mg) were prepared
by the incorporation of indomethacin powder into paraffin
wax (m.p. 43-43°) in the ratio of 1:2 parts by weight. For
control purposes similar implants containing paraffin wax
alone were prepared.
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Active immunization of guinea-pigs The test guinea-pigs
were injected intradermally at multiple sites on the back
with a bovine serum albumin-PGF2(X conjugate (Dighe, Emslie,
Henderson and Simon, 1975) emulsified in Freund's adjuvant.
The total volume injected in each animal was 1.0 ml, con¬
taining the equivalent of 100 Ug of PGF2a. Pertussis
vaccine (0.1 ml) was injected subcutaneously at 2 sites.
The 5 control animals received identical treatment except
that the PGF2a and the bovine serum albumin were not con¬
jugated. Booster injections (1.0 ml) in Freund*s incomplete
adjuvant were given subcutaneously 4 weeks later at 4 sites,
2 suprascapular and 2 in the femoral region.
Determination of antibody levels Blood for antibody level
determination was collected from each animal by cardiac
puncture 4 to 6 months after the initial immunization. The
titre in each serum was estimated using 10 pg 3H-PGF2a
(specific activity 160 Ci/mmol). The reaction volume was
1 ml and the 'titre' was expressed as the dilution of serum
which bound 50% of 3H-PGF20t. Sera were considered not to
have a titre if at a dilution of 1 in 500, the level of
3H-PGF2a bound was similar to that bound in the non-specific
binding tests (about 10%).
Hysterectomy For comparative purposes, three guinea-pigs
were hysterectomized under sodium pentobarbitone anaesthesia
and blood for plasma progesterone determinations was collected
from two of these by cardiac puncture three times weekly.
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RESULTS
Foreign Bodies in the Lumen of Guinea-pig Uterus in vitro
In the first series of experiments the amount of smooth muscle
stimulating activity in the Tyrode's solution bathing the horn
containing polyethylene tubing exceeded that in the incubate
from the control in 8 out of 9 tests (Table 10). None of
the three autacoid antagonists, methysergide, mepyramine or
atropine, abolished the biological activity of the incubate
on the fundus indicating that 5-hydroxytryptamine, histamine
and acetylcholine, responses to which were abolished, were
not present. Moreover, the biological activity remained
after incubation with chymotrypsin (Horton, 1959), showing
that it was not attributable to a smooth muscle stimulating
peptide such as bradykinin, substance P, angiotensin or
oxytocin.
In a further control experiment with one pair of uterine
horns, one horn was incubated in the presence of a piece of
polyethylene tubing (not inserted into the lumen) and the
other horn was incubated alone. There was no difference
between the amount of smooth muscle stimulating activity in
the incubation media of the two horns (equivalent to 7.5 ng
PGF2a/ml), indicating that extraluminal polyethylene tubing
did not affect output. Finally, two pieces of polyethylene
were incubated separately in the absence of uterine tissue;
no prostaglandin could be detected in the incubation medium
of either. It follows therefore that the difference between













Assay of the nine pairs of incubated samples
obtained in the second experiment on the rat
fundal strip
Activity ng of PGE^ml
Test Control
(distended horn) (non-distended horn)
12 7.5
10 2.5
15 n.d. (< 3)
10 10





n.d. No detectable activity
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to the presence of polyethylene tubing within the uterine
lumen. This must stimulate increased release of a smooth
muscle stimulating substance from the uterus.
A further series of experiments were designed to iden¬
tify the active principle. Pooled incubation fluid from 35
pairs of guinea-pig uteri were solvent extracted; the active
principle behaved like a polar acidic lipid on partition.
On silicic acid chromatography the activity in both test and
control samples was eluted with 80% ethyl acetate in benzene
(Fig. 7). This corresponds to the chromatographic behaviour
of authentic PGF2a. In terms of PGF2a the extracts in total
contained 1 Ug PGF2a (test) and 100 ng (control).
Quantitative parallel biological assays provide strong
evidence of identification (Chang and Gaddum, 1933). Assay
of the 'PGF' chromatographic fractions on the rat fundus,
rabbit jejunum, guinea-pig ileum and the ascending colon of
the Mongolian gird (Meriones unguiculatus) showed good
agreement when assayed in terms of PGF2a (Table 11). The
greatest index of discrimination (Gaddum, 1955) between the
unknown and PGF2a was only 2 whereas between the unknown and
the closely related PGE,, it was 297. Moreover, on the
rabbit jejunum contractile responses to PGE, and PGF2CC were
qualitatively different (as described by Horton and Main,
19Q5). The responses to the test sample resembled those to
PGF2(X. This combination of physico-chemical, chromatographic
and biological evidence showed that the active principle was
prostaglandin-like. From the parallel assay results a PGE
could not be the active principle released by uterine distension.
ELUANT- ETHYL ACETATE IN BENZENE
Figure 7 Silicic acid chromatography of extracted
incubation fluid from distended (continuous
line) and non-distended (interrupted line)
horns of guinea-pig uterus in vitro.
Fractions of column effluent were assayed
in the isolated rat fundus strip preparation
Ordinate: biological activity in terms of
pg equivalent of PGF2a. Abscissa: fraction
numbers (l = 30% ethyl acetate in benzene;
2 = 40%; 3, 4 and 5 = 60%; 6 = 80%; 7 = 100%
8 = 100% methanol)


























The evidence strongly suggests that the substance is PGF2a
but it is insufficient alone to prove that this is so (see
Horton and Main, 1967, for the presentation of this argument).
The next experiments were designed to obtain conclusive
evidence . The previous experiment was repeated with a fur¬
ther 35 guinea-pigs and the PGF2a-like material from the
silicic acid column (about 700 ng in the test sample and
80 ng in the control sample as estimated by bioassay) was
subjected to combined GLC/MS. The Me/TMS and Me/TFA deriv¬
atives of the test samples gave gas chromatographic peaks at
19 and 6 minutes respectively corresponding exactly to the
retention times of the same derivatives of authentic PGF2a.
Estimated by the size of the GLC peak, the amount of PGF2a
in the test samples agreed well with the figure obtained by
biological assay. The control sample gave no detectable GLC
peak at these times, presumably due to insufficient material
being present.
Mass spectra of these two derivatives of test and
authentic PGF2a samples were recorded at the maximum of the.
GLC peaks and at the equivalent retention time (for control
samples which showed no GLC peaks). Mass spectra showing
the major m/e peaks above 300 a.m.u. are illustrated in
Figure 8.
The spectrum of authentic PGF2Ct (Me/TMS) had eight
abundant m/e peaks 584 [m+], 569 [m - 15], 513 [m - 7l],
494 [m - 9o], 423 [m - (90 + 71)] , 404 [m - (90 x 2)] ,
333 [m - (2 x 90 + 71)] and 307. These eight peaks were
seen in the mass spectra of the test (distended) sample
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Figure 8 Mass spectra of the Me/TMS derivatives of
control incubate (upper), test incubate
(middle) and standard PGF2a (lower). The
control and test samples were PGF fractions
from incubate extracts of non-distended and
distended horms of guinea-pig uterus in vitro
respectively. Ordinate: relative abundance.
Abscissa: /e. Peaks characteristic of
PGF2a Me/TMS numbered horizontally, other
major peaks vertically.
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but not in the control (non-distended) sample. Moreover,
the heights of the peaks in the test samples are in similar
ratio to those in the authentic PGF2a spectrum. Four other
conspicuous peaks were recorded in the test sample (451,
437, 382 and 361). These were not present in the authentic
PGF2a (Me/TMS) spectrum but were found in similar abundance
in control samples. These peaks can be attributed to the
presence of interfering substances which were common to both
test and control and are not due to the presence of a prosta¬
glandin.
Similar results were obtained with the Me/TFA deriv¬
atives (Fig. 9). The PGF2a (Me/TFA) and test sample had
three conspicuous m/e peaks in common at 542 [m - 14],
426 [m - (2 x 114)] and 314 [m - (3 x 114)] whereas test
and controls had a 326 peak in common which was not present
in the PGF2a (Me/TFA) spectrum.
It was concluded from this evidence that the test
sample contained PGF2a, but that any PGF2(X present in the
control was below the level of detectability.
On the basis of GLC behaviour neither PGF., a nor
5a,7a-dihydroxy-ll-oxo-tetranorprostanoic acid (isolated
from guinea-pig urine where it is the principal PGF2a
metabolite) could be detected in either the test or control
samples.
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Figure 9 Mass spectra of the Me/TFA derivatives of
control incubate (upper), test incubate
(middle) and standard PGF2Ct (lower). The
control and test samples were PGF fractions
from incubate extracts of non-distended and
distended horns of guinea-pig uterus iri vitro
respectively. Ordinate: relative abundance.
Abscissa: /e. Peaks characteristic of
PGF2a Me/TFA numbered horizontally, other
major peaks vertically.
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Treatment with oestrogen Biological assay on the rat
fundal strip of fractions eluted from the silicic acid
column showed the presence of a PGF-like substance in all
seven of the plasma extracts from intact guinea-pigs treated
with oestrogen on days 4 to 6 of the oestrous cycle (Table 12).
None of the (seven) controls contained any PGF-like activity
nor did the oestrogen-treated hysterectomized group. Bio¬
logical assay on the rat fundal strip of fractions eluted
from silicic acid was used to detect PGF-like activity.
In none of the samples (test or control) was any biological
activity detected in other chromatographic fractions. All
values shown in Table 12 have been corrected for 45%
recovery.
Two of the test samples were subjected to GLC/MS after
derivatization. On GLC the Me/TMS gave a peak at the
retention time corresponding to authentic PGF2CX (Me/TMS).
Mass spectra (Fig. 10) showed all the principal m/e peaks
of PGF2a found in previous experiments described previously.
These GLC/MS data confirmed that the substance detected by
biological assay was PGF2(X.
The guinea-pig metabolises PGF2C[ to 5a, 7a-dihydroxy-
11-oxo-tetraprostanoic acid which co-chromatographs with
PGF2a on silicic acid (Horton and Los, unpublished), but
separates from PGF2a on GLC, its Me/TMS derivative having
a retention time of 5.3 minutes (PGF2a Me/TMS 16.6 minutes).
The metabolite isolated from the urine of guinea-pigs
injected with PGF2a (during a study of its luteolytic
activity) was purified and converted to the Me/TMS. Its
TABLE 12 Concentration of PGF2Ct in the utero-ovarian
venous blood collected on day 7 of the
oestrous cycle of oestrogen-treated and
control guinea-pigs
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Figure 10 Mass spectra of the Me/TMS derivatives of
material extracted from the utero-ovarian
venous blood of intact guinea-pigs treated
with oestrogen, of hysterectomized guinea-
pigs treated with oestrogen and intact non-
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Figure 11 Mass spectra of the Me/TMS derivatives of
material extracted from the utero-ovarian
venous blood of oestrogen-treated and non-




mass spectrum (Fig. 11) had the following peaks:
443 [m - 15], 427 [m - 3l] , 368 [m - 9o], 353 [m - (15 + 90)],
281 [m - (87 + 90)] , 278 [m - (2 x 90)] , 254 [m - (114 + 90)] ,
241 [m - (127 + 90)] , and 2177 The molecular ion (458 a.m.u.
was not seen. Of these peaks only the 217 was detected in
any of the blood extracts analysed (Fig.11). It is evident,
therefore, that this metabolite is not found in guinea-pig
utero-ovarian venous blood after oestrogen treatment.
Plasma Levels of Prostaglandins and Progesterone in the Normal
Oestrous Cvcle of Guinea-pigs
Identification of PGF2CC GLC/MS analysis provided conclusive
evidence for the presence of PGF2a in utero-ovarian blood
samples taken from guinea-pigs towards the end of the oestrous
cycle. Under the GLC conditions used in these experiments
the Me/TMS and Me/TFA derivatives of standard PGF2(X had
retention times of 16.6 and 4.9 minutes respectively. Mass
i
spectra were taken at these times of the material in the
column effluent following injection on the GLC of the Me/TMS
and Me/TFA derivatives of the plasma extracts derived from .
day 15 guinea-pigs. The major peaks (above a.m.u.) of m/e
values 584 [m+], 569 [m - is], 513 [m - 7l], 494 [m - 9o],
423 [m - (90 + 71)] , 404 [m - (2 x 90)] , 379 [m - ( 114 +
90 + 1)], 353 [m - (141 + 90)], 333 [ m - (2 x 90 + 71)]
and 307. These peaks were present in approximately the
same ratios in the Me/TMS derivative of the plasma extract
derived from day 15 guinea-pigs. Similarly the Me/TFA deriv¬
ative of oestradiol material and standard PGF2C[ had peaks
in common at m/e values of 542 [m - 114], 511 [m - (31 + 114)],
441 [M - (101 + 114)] , 428 [m - (2 x 114)] , and 314[m - (3 x 114)
again in similar ratios. These GLC/MS results are identical to
to those shown above in Figures 8, 9 and 10. This is
strong evidence for the presence of PGF2a in utero-ovarian
blood collected from guinea-pigs on day 15 of the cycle.
Similar evidence with respect to the Me/TMS derivatives
alone was found for the presence of PGF2a in blood collected
on days 13 and 14 of the cycle. In samples collected on
days 3, 9, 10, 11 and 12 no pattern of mass spectral peaks
characteristic of PGF2a could be discerned. The much
lower concentrations likely to be present (as shown by
biological assay) necessitated the use of the mass spectro¬
meter at a much higher amplification. This increased the
size of peaks from interfering substances and obscured any
signs of the PGF2a spectrum.
No GLC/MS evidence for the presence of PGFia in any
of the samples was obtained.
Identification of PGE2 Identification of PGE2 proved more
difficult. The Me/MO/TMS derivatives of PGE,, PGE2 and the
silicic acid PGE eluates from day 14 and day 15 blood samples
were compared by GLC/MS. The pure prostaglandins had reten¬
tion times of 18.4 (PGE, ) and 14.8 (PGE2 ) for the first
isomer and 22.3 and 18.4 minutes respectively for the second.
So many interfering peaks were present in the derivatized
test sample, however, that it was impossible to discern the
expected prostaglandin m/e peaks. No definite conclusion
could be drawn from this experiment. Analysis by GLC/MS
of day 15 extracts, after chemical conversion of PGE to
PGB prior to derivatization, was more successful. On this
GLC system the Me/TMS derivatives of PGB, and PGB2 each had
a retention time of 17.2 minutes. The mass spectrum of
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pgb, (Me/TMS) had prominent peaks at 422 [m+], 351 [m - vi] ,
and 323 [m - (71 + 28)]. Corresponding peaks for pgb2
(Me/TMS) were 420, 349 and 321. The difference of 2 a.m.u.
is due to the additional 5,6 double bond in pgb2.
A mass spectrum of derivatized day 15 plasma extract
taken at 17.2 minutes contained peaks at m/e values of
420, 349 and 321 in the ratio of 4:1:1. .This ratio is
characteristic of PGB2 (Me/TMS) (see Fig. 6)
However, these three peaks, although clearly visible, were
smaller than several other peaks in the spectrum due to
the presence of other substances in the extract. It was
significant, however, that there were no peaks at m/e
values of 422, 351 and 323 - the peaks characteristic of
PGB, (Me/TMS). On the basis of this evidence it can be
seen that PGB2 but not PGB, was present in the final
extract. This must have arisen from PGE2 in the original
plasma extract, since any PGA2 or PGB2 in the original
plasma would have been separated from the PGE2 by silicic
acid chromatography (see p. 20) prior to the chemical con¬
version of PGE2 to PGB2. It is concluded that the PGE-like
material extracted from utero-ovarian venous blood on day 15
as detected and measured by biological assay can be identi¬
fied as PGE2 on the basis of mass spectral data.
Levels of prostaglandins in the utero-ovarian blood
of guinea-pigs during the oestrous cycle
The concentrations of PGF2CC and PGE2 in pooled samples
of blood collected from animals on days 3, 7 and 9 to 15
of the oestrous cycle were determined by biological assay
and the results corrected for recovery are shown in
Table 13 and Figure 12. The mean values for day 7 were
taken from the assays performed on control animals des¬
cribed above (Table 12, p. 75).
The level of PGF2a on day 3 was 14 ng/ml. This had
fallen to below detectable limits (<3 ng/ml) on day 7,
but on days 9 and 10 low levels (5 and 4 ng/ml ) were
present. The concentration then rose to 17 ng/ml on day 11
and remained around that level until day 15 when it again
rose sharply to 61 ng/ml.
PGE2 was not detectable in blood collected on days
3, 7, 9, 10, 11 and 12. It was just detectable (l ng/ml)
on day 13 and then rose sharply to 5 ng/ml (day 14) and
55 ng/ml (day 15).
Losses in derivative formation and during GLC/MS
(particularly with PGE2 ) probably accounted for the some¬
what lower levels as measured by GLC/MS compared with
bioassay.
Figure 12 The relationship between the concentrations
of PGF2a ( ) and progestin ( ; mean +
s.e. of the mean) in utero-ovarian venous
blood of guinea-pigs at different stages of
the oestrous cycle.
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TABLE 13 Concentrations of PGF2a and PGE2 in the
utero-ovarian venous blood of guinea-pigs
during the oestrous cycle











TABLE 14 Total plasma progestin levels (ng/ml) in
utero-ovarian venous blood of guinea-pigs
during the oestrous cycle (base line value,
i.e. mean for guinea-pigs with no corpora
lutea in appropriate ovary = 40.0 ng/ml)
„ „ , Mean concentration total progestinsDay of cycle (ng/ml plasma ^ s.E. of mean)
3 65.9 + 12.3
9 126.0 + 31.0
10 108.2 + 15.2
11 94.9 + 37.9
12 177.2 + 31.8
13 81.1 + 22.1
14 105.9 + 30.0
15 45.1 + 10.0
85
Levels of progesterone in utero-ovarian venous blood
of guinea-pigs during the oestrous cycle
The mean levels of plasma progesterone (+ standard
error of the mean) found in the utero-ovarian vein of guinea-
pigs throughout the oestrous cycle are given in Table 14.
From a low value on day 3 (66 ng/ml), the level rose and
between days 9 and 14 values of 80 - 180 ng/ml were recorded.
A fall to 45 ng/ml occurred between days 14 and 15 which
represents near basal levels because the concentration of
progesterone in the utero-ovarian venous plasma of guinea-
pigs having no corpora lutea in the ipsilateral ovary was
40 ng/ml.
Effect of indomethacin on the length of the oestrous cycle
Subcutaneous injections of indomethacin The mean length of the
oestrous cycle in guinea-pigs injected subcutaneously with
indomethacin (20 mg/day) from the 7th day of the cycle until
the onset of the next cycle was 19.3 +_ 0.5 days (n = 12).
This result was significantly greater (P <0.001) than the
length of cycles of the same guinea-pigs before and after
indomethacin treatment. It was also significantly greater
than the cycles of control guinea-pigs injected with vehicle
alone, and of animals injected with a lower dose of indomethacin
(4 mg/day). These results summarized in Table 15, indicate
that indomethacin at the higher dose, but not at the lower
dose, has a significant effect in increasing the length of
the oestrous cycle. However, at the 20 mg/day level, the
indomethacin caused toxic effects, two of the animals died
after 11 days of subcutaneous injections.


















Intra-uterine indomethacin In six guinea-pigs, implants
of paraffin wax containing indomethacin were placed in each
uterine horn, whilst in the six control animals paraffin
wax alone was inserted. The results are shown in Table 16.
The length of the three oestrous cycles before operation
in each of the 12 guinea-pigs was estimated. The mean
lengths of 16.4 + 0.2 (n = 18) and 16.6 + 0.2 (n = 18) days
for the two groups were not significantly different. In
the six guinea-pigs receiving paraffin wax implants without
indomethacin the mean length of the cycles during which the
operations were performed was 19.5 + 1.0 days and the mean
length of the three subsequent cycles was 14.8 + 0.2 days.
In contrast, in each of the guinea-pigs receiving intra¬
uterine indomethacin implants, the cycles in which the
operations were performed were all in excess of 47 days.
Three of these guinea-pigs were killed on the 47th day for
assessment of luteal function (see below). The remaining
three came into oestrus after cycle lengths of 75, 70 and
51 days. The first of these three had a subsequent cycle
of 49 days and was then killed on the 8th day of the next
cycle. The second was killed on the 9th day of the first
post-operative cycle and the third had two post-operative
cycles of 17 days before being killed on the 9th day of
the next cycle.
In two further guinea-pigs implanted with intra-uterine
indomethacin, 5 cycles of 15.8 +1.0 and 15.4 +1.0 days
each were observed before implantation. Subsequently, the
first of these guinea-pigs had cycle lengths of 72 and











over 62 days and the second had cycles of 30, 24, 15, 29,
16 and more than 41 days. Elevated plasma progesterone
levels were maintained throughout the elongated cycles
and in some cases the levels were higher than normal
(Fig. 13).
Assessment of luteal function The six control animals
which received paraffin wax implants without indomethacin
were allowed to come into oestrus four times following the
operation. During the next cycle three were killed on the
8th day and three were killed on the 14th or 15th day of
the cycles. These times corresponded to low and high
uterine output of prostaglandin F2a as shown above. Of the
six animals with indomethacin implants, three were killed
37 days after the operation (on the 47th day of the cycle)
whilst three were killed on the 8th or 9th day of a sub¬
sequent cycle. Luteal function was assessed independently
and blindly by two workers using histological measurement
and blood progesterone measurement respectively. The
results are shown in Table 17.
The plasma progesterone levels of three guinea-pigs
treated with indomethacin and killed on day 8 or 9 were
2.4, 3.1 and 3.6 ng/ml whereas the levels of indomethacin-
treated guinea-pigs which had still not come into oestrus
when they were killed on the 47th day of the cycle were 3.8,
8.8 and 8.9 ng/ml. The mean sizes of the corpora lutea
were 3.8, 2.9, 3.1 and 4.3, 4.3 and 6.0 mm3 respectively.
In the last two guinea-pigs corpora lutea resembled those
seen in hysterectomized guinea-pigs. In the control animals
Figure 13 Effect of intra-uterine indomethacin
(33 mg/horn) implants inserted at X on
the progesterone levels (ordinate) of
guinea-pigs. Beginning of each cycle
shown by vaginal smears is indicated by
a black square; the numbers on the
abscissa refer to the length of each
cycle.




































on day 8, plasma progesterone levels ranged from 4.6 to
6.8 ng/ml and the corpora lutea sizes from 2.0 to 3.1 mm3.
In those killed at the end of the cycle, plasma progest¬
erone levels were within the range of 0.3 to 0.6 ng/ml.
The corpora lutea sizes ranged from 0.6 to 1.0 mm3 and
had clearly regressed.
These results show that elongation of the cycle follow¬
ing intra-uterine implantation of indomethacin is associated
with retention of functioning corpora lutea.
Autopsy examination of the uterus Uteri from both control
and treated guinea-pigs were hypertrophied and contained
intraluminal fluid in amounts ranging from 1.5 to 63 ml
The fluid was slightly alkaline (pH 8). There
was no difference macroscopically or microscopically between
indomethacin-treated and control animals.
Effect of active immunization against PGF^ on length of the
oestrous cycle
The results on cycle length following active immuniz¬
ation against PGF2a are summarized in Figure 14. In the con
trol animals injected with the mixture of bovine serum albumi
and PGF2a no significant change in length of oestrous cycle
occurred (before injection, 16.3 + 0.3 days, n = 29; after
injection, 16.4 + 0.2 days, n = 50). In guinea-pigs injected
with the conjugate of bovine serum albumin and PGF2a, the
cycle lengths before injection (16.5 +0.2 days) were not






Figure 14 Effect of active immunization against PGF2CC on
oestrous cycle length in guinea-pigs.
Ordinate: oestrous cycle length in days.
Abscissa: numbers of successive cycles recorded;
arrows indicate time of injection.
Upper row: 5 control animals injected with a
mixture (non-conjugated) of PGF2a and bovine
serum albumin. Lower row: 5 animals injected
with a conjugate of PGF2a with bovine serum
albumin and a sixth animal which was hysterect¬
omized (but not immunized).
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oestrous cycles of normal length followed the initial
injection. The length of their cycles then greatly pro¬
longed, approximating to that produced by hysterectomy (see
below). In the fourth guinea-pig, one cycle of normal length
was followed by a cycle of 48 days; thereafter the cycles
were 23 to 25 days in duration. All these increases in length
were significant (P <0.01). In the fifth animal, there was
a small but significant increase (P <0.05) from 16.7 + 0.4
to 18.8 +0.5 days.
The vaginal histological changes were less abrupt and
less definite in the animals with prolonged cycles than in
animals with cycles of normal duration. This is represented
by the hatched areas in the columns in Figure 14. In spite
of this lack of precision about the exact day of vaginal
cornification and leucocytic influx, there is no doubt that
the oestrous cycles were prolonged.
When this study was completed the five control guinea-
pigs were themselves immunized against PGF2a» AH five showed
elongated cycles (Table 18).
Serum levels of PGFga antibody There was some correlation
between the titre level and the degree of elongation of
oestrous cycle in the seven immunized guinea-pigs in which
titres were measured. The results are summarized in Table 19.
In four guinea-pigs with cycles longer than 70 days after
immunization there was a 50% binding at dilutions ranging
from 1 in 1300 to 1 in 3200. In the three guinea-pigs with
cycles in which maximum elongation of any cycle was 48, 28
and 19 days, the binding at 1 in 500 dilution was 31, 26 and
10% respectively. In the 5 control animals (prior to




TABLE 19 Antibody titres and length of longest
post-immunized cycles in guinea-pigs
immunized against PGF2a
Titre: Longest
Guinea-pig 50% binding cycle recorded
at a dilution of (days)
1 1 in 3200 80
2 1 in 2800 100
3 1 in 1300 78
4 (31% at 1 in 500) 48
5 (10% at 1 in 500) 19
R 1 in 1800 96
P (26% at 1 in 500) 28
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their subsequent immunization), the binding of tritiated
PGF2a at a serum dilution of 1 in 500 ranged from 7 to 12%.
These figures are not regarded as different from the non¬
specific binding level of 10%.
Plasma progesterone levels in immunized guinea-pigs In five
guinea-pigs plasma progesterone levels were measured before
and after immunization three times weekly. This blood samp¬
ling technique did not affect cycle length in other guinea-
pigs nor in these guinea-pigs prior to immunization. These
five guinea-pigs had 17 or 18 normal cycles prior to immuniz¬
ation. After immunization against PGF2a all had elongated
cycles and in all five progesterone levels were maintained
at luteal levels or higher throughout the lengthened cycles.
One of these is illustrated in Figure 15.
Plasma progesterone levels in hysterectomized guinea-pigs
Three guinea-pigs were hysterectomized. The first (data shown
in Fig. 14) had the expected elongated cycle following the
operation but no blood samples were collected. Cardiac
blood was collected from the other two guinea-pigs before
and after hysterectomy. Unfortunately the first of these
died on the 19th day of the post-operative cycle but abnor¬
mally high levels of progesterone were found on days 13, 16
and 18 and functional corpora lutea were still evident at the
time of death. The second of these guinea-pigs (Fig. 16)
had cycles of 117 and 127 during which high levels of plasma
progesterone were maintained. This clearly demonstrates that
removal of the uterus results in maintenance of functional
corpora lutea in the ovaries throughout these abnormally
long cycles.
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Figure 15 Plasma levels of progesterone in a guinea-pig
immunized against PGF2a. At I, the animal
was immunized and at B, booster injections
were given. The beginning of each cycle is
indicated by a black square, the numbers on
the abscissa refer to the length of each
cycle.
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Oestrous cycle length (days)
Figure 16 Effect of hysterectomy on plasma progesterone
levels in the guinea-pig. Ordinate: plasma
concentration. Abscissa: length of two
successive cycles following the operation -
the beginning of each cycle is indicated by a




Guinea-pig uterus distension in vitro
Distension of the guinea-pig uterus with beads in vivo
results in premature luteolysis (Donovan and Traczyk, 1962).
The evidence from the present experiments, in vitro, shows
that distension with polyethylene tubing causes the guinea-
pig uterus to release PGF2(X in about 10 times the amounts
released in absence of distension. The evidence of identifi¬
cation is based upon partition properties and chromatographic
behaviour which suggest that the active principle is a
prostaglandin-like lipid, quantitative biological assay which
exludes PGE, (and PGE2 ) but is suggestive of PGF2a and,
most conclusively, GLC/MS which shows the presence of PGF2a
by GLC peaks and by characteristic MS in the samples collected
from uterine horns which had been distended. The evidence
excludes PGE1} PGF1CC and the main guinea-pig urinary metabolite
of PGF2a but it does not exclude the additional presence of
all other prostaglandins. However, the close quantiative .
agreement between the estimates of PGF2a concentration by
biological assay and by gas chromatography indicates that
PGF2a can account for all the biologically-active material
released from the uterus as originally detected by the use
of the rat fundal strip.
PGF2a is luteolytic in many species (Pharriss and Wyngarden,
1969; Kirton, Pharriss and Forbes 1970) including the guinea-
pig (Blatchley and Donovan, 1969). The amounts of PGF2CC
needed to produce this luteolytic effect are far in excess of
the amounts that were released from the uterus in the experiments
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reported here. It is probable that this discrepancy can
be attributed to the difficulty in injecting PGF2a in a
way which mimics the presumed physiological mode and rate
of release. For example, 95-99% of any PGF2a injected
parenterally and hence passing through the pulmonary circu¬
lation, will be taken up and metabolised (Ferreira and Vane,
1967) before it can reach a target organ, whilst further
metabolism occurs in the liver and elsewhere.
The evidence regarding the role of PGF2Ct in physiological
luteolysis can at this point be summarized as follows:
distension of the uterus is known to induce luteolysis.
PGF2a is known to be luteolytic, the present study has shown
that distension of the uterus releases PGF2a. This provides
good preliminary support for the hypothesis that the uterine
luteolytic hormone in the guinea-pig is PGF2a. Since this
work was completed,in vivo experiments have shown that inser¬
tion of beads into the uterus of the guinea-pig increases the
output of PGF2a in the utero-ovarian venous blood, decreases
the size of the corpora lutea and reduces the level of
progesterone (Blatchley, Donovan and Poyser, 1976).
Oestrogen treatment It is well established that oestrogen
treatment of guinea-pigs early in the oestrous cycle causes
premature luteolysis. This could be due to an action on one
or more of several sites, notably the pituitary (Anderson ei
al., 1969). However, the demonstration that this luteolytic
action is abolished by hysterectomy (Bland and Donovan, 1970)
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reaffirms the importance of the uterus in this mechanism.
It seemed probable that oestrogen might be acting upon the
uterus to cause premature release of the uterine luteolytic
hormone in a similar manner to that occurring after the
insertion of foreign bodies within the lumen as discussed
above. Knowing that such distension causes the release
of PGF20t it was logical to look for similar release in .
response to oestrogen.
In this series of experiments the biological preparation
used and the protocol were exactly the same as those used to
demonstrate the luteolytic effects of oestrogen. Under these
conditions an increased output of PGF2a in the utero-ovarian
vein in response to oestrogen has been demonstrated. That
the PGF2a arises from the uterus and not elsewhere, particu¬
larly the ovary, is shown by the absence of any PGF2CX in the
plasma sample collected from hysterectomized animals after
treatment with oestrogen. That PGF2(X is released in response
to oestrogen is shown by its presence in all seven test
samples and its undetectability in the seven controls. In
one control sample the limit of detectability by bioassay
was high, otherwise each test was higher than its corres¬
ponding control (Table 12). Identification again has been
obtained by GLC/MS analysis which conclusively demonstrates
the presence of PGF2a.
The mechanism of the luteolytic action of oestrogen
can therefore now be explained as follows: the oestrogen
stimulates the uterus to produce and release increased
quantities of PGF2a, which in turn reaches the ovary to exert
103
its luteolytic action by a route and a mechanism as yet
unknown. It seemed possible that a similar mechanism
could be involved physiologically in the normal oestrous
cycle of the guinea-pig if PGF2CC production by the uterus
increases under the influence of oestrogen secretion from
the growing follicles in the ovary. This possibility was
therefore examined next.
Oestrous cycle Measurement of PGF2a levels in uterus
venous blood collected on different days of the oestrous
cycle revealed a cyclical variation in the amount of PGF2a
released. The moderately high levels of PGF2a on day 3
probably reflect the tail of the peak rise at the end of
the cycle. Thereafter the levels remained low but detectable
until day 11 when they rose to around 17 ng/ml at which they
remained until between day 14 and day 15. While PGF2a levels
were low progesterone levels were high, ranging from 85 to
170 ng/ml, but by day 15 the progesterone concentration had
halved and was close to basal levels whereas the PGF2a con¬
centration had almost quadrupled and was 60 ng/ml. It is
not known how much of this PGF2a would have reached the
corpora lutea.
The level of progesterone in utero-ovarian venous blood
was about forty times greater than that found in the systemic
blood at the same stage of the cycle (Blatchley, personal
communication). The large variation between individual
guinea-pigs, indicated by the large standard error, can be
explained, to some extent, by the different amounts of luteal
tissue in the ovary on the side from which blood was collected.
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The demonstration of an in vivo release of PGF20t during
the oestrous cycle and prior to the onset of physiological
luteolysis is further persuasive evidence in support of the
hypothesis that this substance is the uterine luteolytic
hormone in guinea-pigs.
Effect of indomethacin The plasma half-life of indomethacin
in the guinea-pig following intravenous injection is short
(20 minutes) and the uterus takes up very small amounts
(Hucker, Zacchei, Cox, Brodie and Cantwell, 1966). These
facts may account for the high dose levels (20 mg/day)
required to cause a significant increase in the length of
the oestrous cycle when indomethacin was injected subcutane-
ously. Certain tissues, notably the small intestine, con¬
centrate indomethacin above plasma levels and it is signifi¬
cant that in this study two animals died with gastro-intestinal
perforations after 11 days of subcutaneous indomethacin treat¬
ment.
The increase in cycle length following indomethacin
injections at the 20 mg/day level is compatible with the
hypothesis that indomethacin blocks formation of luteolysin
in the uterus and thus prolongs the life of the corpora lutea.
Similar results were obtained by Marley (1973) following daily
oral administration of indomethacin (40 mg/kg) beginning on
day 11 of the cycle. It is probable, however, that prosta¬
glandin synthesis was also blocked at many other sites in the
body and that these could have contributed to the overall
picture. It was therefore important to try to localize
the site of action of indomethacin and for this purpose a
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method was devised with the aim of producing a high con¬
centration of indomethacin near the site of formation of
luteolysin, namely the endometrium. The indomethacin was
mixed with paraffin wax to form a slow release formulation.
Although the total amount of indomethacin placed in each
uterine horn was high (33 mg), subsequent analysis of the
implants removed at autopsy indicated that the quantities
of indomethacin released in each uterine horn ranged from
0.2 to 0.6 mg/day. This dose released in the neighbourhood
of the endometrium over a prolonged period was sufficient to
produce a considerable increase in the length of the oestrous
cycle.
In three of the guinea-pigs treated with intra-uterine
indomethacin, vaginal smears showed that oestrus had still not
occurred up to the 47th day when the animals were killed. The
plasma progesterone levels at this time were high (see Table
17), the normal peak of plasma progesterone levels being about
3 ng/ml. The corpora lutea were larger than normal resembling
those produced by hysterectomy (Rowlands, 1961). In the other
three treated guinea-pigs, cycles greatly in excess of normal
were observed, their length being similar to that seen in
hysterectomized guinea-pigs (Loeb, 1923 and see below).
When these animals were killed during a subsequent cycle, the
progesterone levels and corpora lutea size were normal for
the time of the cycle (8 or 9 days) (Challis, Heap and
Illingworth, 1971; Bland and Donovan, 1965).
The three control animals killed at the end of the cycle
had progesterone levels within the normal range for that time.
106
The corpora lutea were typically small and had regressed.
The control animals killed at mid-cycle, however, had
elevated plasma progesterone levels but the corpora lutea
were within the normal range. This may be associated with
the finding that these guinea-pigs were exhibiting shonter
oestrous cycles. In the six control animals, the cycle
in which the paraffin wax implants were inserted was
slightly but significantly prolonged (P <0.001) whereas the
subsequent cycles were slightly but significantly shortened
(P <0.001). These results are identical to those of
Ginther (1969) and are probably attributable to the uterine
ligation.
It is now well established that indomethacin blocks the
biosynthesis and release of prostaglandins (Vane, 1971). If
the effects observed here following intra-uterine adminis¬
tration of indomethacin are attributable to this mechanism,
further evidence is provided in support of the hypothesis
that the uterus exerts its luteolytic influence upon the
ovary by the formation and release of PGF2a.
Active immunization Immunization of adult female guinea-
pigs using a conjugate of PGF2CC with bovine serum albumin
was followed by an increase in length of oestrous cycles in
9 out of 10 animals. These changes were associated with
elevated plasma progesterone levels lasting for the duration
of the elongated cycles in 5 of the guinea-pigs in which
measurements were made. These results complement those with
indomethacin and the effects like those of intra-uterine
indomethacin resemble the changes seen after hysterectomy
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(compare Figs. 13, 15 and 16). The mechanism may be envis¬
aged as follows: PGF2(1 is synthesised by the uterus towards
the end of the cycle and released into the uterine vein.
There it is neutralised by PGFaa antibodies in the plasma
thus preventing free PGF2a from reaching its target in the
ovaries in sufficient concentration. Hence the corpora
lutea do not receive the stimulus to regress at the normal
time and cycles are prolonged with continued luteal function.
Another interpretation of these results is that immuniz¬
ation has interfered with other actions of PGF2a elsewhere.
For example, there is evidence in some species that prosta¬
glandins are involved in the release of gonadotrophins
(Armstrong and Grinwich, 1972; Behrman, Orczyk and Greep,
1972; Carlson, Barcikowski and McCracken, 1973; Harms,
Ojeda and McCann, 1974; Sato, Taya, Jyujyo, Hirono and
Igarashi, 1974) and in ovulation (Armstrong and Grinwich,
1972; Grinwich, Kennedy and Armstrong, 1972; 0'Grady,
Caldwell, Auletta and Speroff, 1972; Orczyk and Behrman,
1972; Tsafriri, Lindner, Zor and Lamprecht, 1972; LeMaire,
Yang, Behrman and Marsh, 1973; Armstrong, Grinwich, Moon
and Zamecnik, 1974). If PGF2a is physiologically involved
in gonadotrophin release, blockade of this release would pre¬
sumably inhibit all cyclical behaviour (ovulation and lutein-
ization with its corresponding increase in progesterone levels)
after the first set of corpora lutea had regressed. This was
not seen in any of the immunized guinea-pigs in this study.
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It- is not known whether ovulation was blocked in the
immunized animals. It is possible that progesterone levels
were maintained by secretions from luteinized non-ovulated
follicles, as reported by others using indomethacin (Armstrong
and Grinwich, 1972; Behrman et; al. , 1972; Grinwich ejt al. ,
1972; O'Grady et al., 1972). It is not known whether
luteinized non-ovulated follicles would be susceptible to
the luteolytic actions of PGF2a.
Yet another explanation of the effects of immunization
could be that it interfered with histological changes in the
vaginal epithelium thus masking otherwise normal cyclical
activity. This possibility is ruled out, however, by the
plasma progesterone levels which clearly reflect a continu¬
ously prolonged period of luteal function. This evidence in
turn may be criticized on the grounds that the radioimmuno¬
assay method may not have been specific for progesterone.
Cross-reactivity studies (Table 9) with a variety of related
steroids indicated, however, that the most likely interfering
compounds can be ruled out.
The most reasonable explanation therefore of these
results from active immunization is that PGF2Ct after its
release from the uterus into the uterine vein is being bound
by the circulating antibody before it can exert its normal
luteolytic action. In conjunction with the preceding evidence
it can be regarded as yet further support for the hypothesis




The original work of Loeb (1923) clearly showed that
removal of the uterus in the guinea-pig results in a greatly
elongated oestrous cycle. This has been amply confirmed by
others as well as by the present study which has also pro¬
vided convincing biochemical evidence of the retention of
functional corpora lutea. It is also apparent in the guinea-
pig that ovarian cyclical activity is controlled by the ipsi-
lateral uterine horn and that the factor responsible is
humoral, probably a substance originating in the endometrium.
If this postulated uterine luteolytic hormone is physio¬
logically important for the control of oestrous cycle length,
it must be released from the uterus towards the end of the
cycle to initiate regression of the corpora lutea. Two
stimuli believed to release the luteolytic substance are
the presence of foreign bodies in the uterine lumen and the
administration of oestrogen early in the cycle.
Since prostaglandin F2a possesses luteolytic activity
(Pharriss and Wyngarden, 1969; Bland and Donovan, 1969),
and since this prostaglandin is synthesised by an enzyme
system which is widely distributed in tissues, it seemed
reasonable to propose as a working hypothesis that the
uterine luteolytic hormone in the guinea-pig is identical
to this prostaglandin.
The cumulative evidence obtained from this study all
tends to confirm that this hypothesis is true. Foreign
bodies in the uterine lumen and pre-treatment with oestrogen
both caused PGF2a release, whilst uterine venous blood from
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the 11th day of the cycle onwards contains increasing
amounts of PGF2a. Indomethacin blocks the biosynthesis of
all prostaglandins and when injected subcutaneously, or more
especially when implanted into the uterine lumen, this drug
mimics the effects of hysterectomy. A similar interference
with the normal luteolytic mechanism follows active immuniz¬
ation of female guinea-pigs against PGF2a.
Thus PGF2a, a natural luteolytic substance, is released
from the uterus at the times when the uterus is thought to
release a luteolytic substance, whilst the blockade of the
synthesis or actions of PGF2a also blocks the normal luteo¬
lytic mechanism in guinea-pigs.
This cumulative evidence clearly points to the identical
nature of PGF2(X and the uterine luteolytic hormone. It does
not however provide any evidence as to how the PGF2a reaches
the ovary from the uterus. Its presence in the uterine vein
suggests a vascular route but the vascular association of the
ovarian artery with the utero-ovarian vein, which is seen in
the sheep, is not immediately apparent macroscopically in the




Discovery of Prostaglandins in the Urogenital Tract
Prostaglandins were first discovered in the urogenital
tract, hence their name. Von Euler discovered them in
human seminal plasma and in extracts of sheep prostate and
vesicular glands. At first it was believed that the
prostaglandins were from the prostate which comprised the
bulk of this combined tissue but in fact they are made in
far greater abundance by the sheep vesicular glands.
Evidence that the seminal vesicles produce a substance of
the prostaglandin type had previously come from von Euler's
discovery of vesiglandin in monkey seminal vesicles. Both
prostaglandin and vesiglandin lowered arterial blood pressure
when injected into anaesthetized animals but only prostaglandin
contracted isolated non-vascular smooth muscle preparations.
The subsequent discovery that prostaglandins of the A series
also lower blood pressure (Lee et al.. 1967; Horton and
Jones, 1969) but lack appreciable smooth muscle stimulating
activity raised the possibility that vesiglandin was likely
to be a prostaglandin A (see Horton, 1972). It seemed
unlikely that this vesiglandin could have arisen artefactu-
ally from a PGE during von Euler's extraction procedure
because he has used the identical methodology to demonstrate
the presence of 'prostaglandin' in sheep prostate/vesicular
glands and this was later shown to be a mixture of PGE and
PGF.
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More recently Kelly and Taylor (1976) discovered that
semen of primates contains prostaglandins of the 19-hydroxy-
PGE group. These prostaglandins (also found in human semen)
are so far believed to be peculiar to the male reproductive
tract. Under von Euler's extraction conditions these
would have been very readily dehydrated to the correspond¬
ing 19-hydroxy-PGA or 19-hydroxy-PGB compounds (the form
in which these compounds were first reported in human semen -
Hamberg and Samuelsson, 1966). It has been suggested by
Kelly, Taylor, Hearn, Short, Martin and Marston (1976)
that von Euler's vesiglandin was a 19-hydroxy-PGE. It seems
more likely, however, that a 19-hydroxy-PGE was the starting
material in von Euler's extracts but that what he extracted,
detected biologically and called vesiglandin was the corres¬
ponding 19-hydroxy-PGA. Certainly, 19-hydroxy-PGA compounds,
like vesiglandin, do lower arterial blood pressure (Horton
and Jones, 1969).
The now classical work of Bergstrom and Sjovall (1960a, b)
on the ram seminal vesicles and on human semen (Bergstrom,
Krabisch and Sjovall, 1960) amply confirmed all von Euler's
work, clearly established the existence of at least two new
natural substances and demonstrated that they possessed a
chemical structure completely novel amongst natural products,
at least in the Animal Kingdom (Bergstrom et al., 1963).
Final proof of the true origin of prostaglandins from
seminal vesicles was furnished by the demonstration of
their biosynthesis in remarkably high yield from arachidonic
acid by an enzyme complex in ram seminal vesicles (van Dorp,
et al.. 1964; Bergstrom et al.f 1964)
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Even before the isolation of prostaglandins by
Bergstrom and Sjovall, there was evidence for the presence
of lipid substances of the prostaglandin type in several
non-reproductive organs. These had been given trivial
descriptive names, for example, irin extracted from rabbit
iris (Ambache, 1957, 1959), darmstoff from the gut (Vogt,
1949), medullin from the kidney (Lee, Covino, Takman and
Smith, 1965) and the menstrual stimulant from human endo¬
metrium (Pickles, 1957). Shortly after the announcement
of the chemical structures of the first prostaglandins
isolated from organs of the male reproductive tract,
Pickles and Raphael reported that certain tissues of the
female reproductive tract, namely human endometrium and
menstrual fluid, also contain prostaglandins - PGE2 and
PGF2CX (Eglinton, Raphael, Smith, Hall and Pickles, 1963).
This finding raised not only the important question of
the physiological role of prostaglandins in the uterus
but also the biological significance of the wider dis¬
tribution of prostaglandins, until then believed to be
derived only from reproductive organs of the male.
Almost simultaneously PGF2a was isolated from the lungs
(Bergstrom, Dressier, Krabisch, Ryhage and Sjovall, 1962)
and very soon many organs were shown to contain prosta¬
glandins (Bergstrom, 1967). Already medullin, a new
compound of unknown structure, had been demonstrated in
the medulla of the rabbit kidney (Lee, et al., 1965).
The active principle, like vesiglandin, lowered arterial
blood pressure but had little effect on non-vascular
smooth muscle. In the light of the results of Bergstrom
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and his school further investigation revealed in the
medullary extracts the presence of three prostaglandins -
PGE2, PGF2a and PGA2 (the original medullin) (Lee, et al..
1967; Daniels, et al.. 1967). PGA2 may conceivably have
been formed artefactually from PGE2.
Thus three of the principal organs of the urogenital
tract were shown at an early stage to contain (and sub¬
sequently shown also to synthesize) prostaglandins of the
E, F and possibly A series. However, in view of their
wide distribution throughout the body and of the equally
wide distribution of the enzyme system, prostaglandin
synthase, it could not be argued that prostaglandins had
a role peculiar to the urogenital tract. Likewise it
could not be argued that their urogenital distribution in
some way reflected the common embryological origin of tissues
of the urinary and reproductive tracts. It seemed probable
that prostaglandins might be implicated in biochemical mech¬
anisms common to many different cell types (just as cyclic
3' 5'-adenosine monophosphate has been shown to be) and that
this mechanism might be expressed by quite different physio¬
logical functions in different cells.
It was therefore decided to examine separately the role
of prostaglandins in three systems of the urogenital tract -
namely, the kidney, the male reproductive tract and the
female reproductive tract.
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Concepts of Chemical Mediation
Although claims about the therapeutic efficacy of
various animal tissue extracts have been made from the
earliest medical times, it was not until the nineteenth
century that research into biological activity of such
extracts began in earnest, thus heralding the dawn of
the Science of Endocrinology. Some of the earliest
experiments were on endocrine organs, notably the adrenals,
thyroid, gonads and pituitary, leading to the eventual
isolation of adrenaline, thyroxine and other classical
hormones. Extracts of non-endocrine tissue also proved
fruitful, indeed it was the discovery of secretin, extracted
from the small intestine by Bayliss and Starling (1902)
that led to their introduction of the term hormone, for a
substance which is secreted by one organ or tissue, circu¬
lates in the blood and acts upon a target organ elsewhere
in the body, in the case of secretin, the exocrine cells of
the pancreas.
A further boost to interest in this field of the
pharmacology of natural products - drugs of animal origin -
came from the work of Loewi and of Dale and his school
(see Dale, 1965). In particular must be mentioned their
demonstration of acetylcholine as the chemical transmitter
at nerve endings. This introduced a completely new concept
namely that neurones secrete chemicals which transmit
their message onwards. During this work on the search for
chemical transmitters,von Euler came to work in Dale's
laboratory and in collaboration with Gaddum discovered
substance P (Gaddum and von Euler, 1931), a peptide
which has now been shown to be a transmitter in the central
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nervous system. It was after his return to Stockholm
that von Euler, continuing in this theme, made the funda¬
mental discovery which led to his recognition of the prosta¬
glandins as a new group of natural products.
In both the hormone and transmitter fields, the sequence
of events and line of reasoning which have led to the recog¬
nition of the physiological role for a natural substance
have been similar. Often the existence of the natural
substance as a normal constituent of some animal tissues
has been detected first by its pharmacological activity on
a biological preparation. The biological actions of the new
substance are then observed to include one or more that
mimic the effects of some physiological response (for example,
the injection of noradrenaline mimics the effect of stimu¬
lating the adrenergic nervous system; the injection of
Cortisol mimics the effect of stimulating the adrenal cortex
with corticotrophin). Measurement of the release of the
natural product from an organ in response to such a physio¬
logical stimulus provides the next line of evidence.
Finally, if the natural product is implicated as a mediator,
blockade of its action or of its formation and release will
abolish the physiological response to stimulation: con¬
versely, blockade of an enzyme system which inactivates the
mediator will potentiate the responses. In all these lines
of evidence quantitative considerations are paramount.
In general, a similar approach has been used in the
investigations reported in this thesis except that the
release of a prostaglandin has been demonstrated in each
case before the pharmacological one of relevance to the
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system in question has been reported - in this study the
latter have been reported by workers elsewhere, namely the
action of PGE2 on adrenergic nerve terminals in the rabbit
kidney (Frame and Hedqvist, 1975) and the luteolytic action
of PGF2a first in the rat (Pharriss and Wyngarden, 1969)
then in other species including the guinea-pig (Blatchley and
Donovan, 1969). Experiments on release in response to a
physiological stimulus (e.g. renal nerve stimulation, hormonal
changes of the oestrous cycle) have three aspects - first
detection, usually by means of biological activity, then
identification by GLC/MS and lastly measurement. The
validity of the methods used is discussed below. Finally,
the effect of blocking prostaglandin release by inhibiting
fatty acid cyclo-oxygenase with aspirin or indomethacin and
the effect of immunization in the investigation of luteolysin
was tested to determine the effects on the physiological
response of interfering with the presumed normal action of
the mediator. The lack of selective prostaglandin antagonists
ruled out the possibility of testing the effect of blocking
the actions of prostaglandins at the receptor level.
Validity of the Methodology
(a) Pharmacological experiments Pharmacological observations
reported by others were crucial to the argument that prosta¬
glandins E2 and F2a have physiological roles at adrenergic
nerve endings and in luteolysis respectively. The inhibitory
effect of PGE2 on noradrenaline release from adrenergic
neurones in the rabbit kidney was demonstrated by infusing
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intra-arterially in the isolated kidney perfused with
a saline solution. Such a preparation is necessarily
subjected to abnormalities of osmolarity and of oxygen
tension and thus must be increasingly unphysiological the
longer the experiment proceeds. Evidence about the via¬
bility or otherwise of the tissue might have been obtained
had measurements of renal function been made. Certainly
in other (unpublished) experiments the author has found
that both the dog spleen and guinea-pig lungs may become
grossly oedematous after more than 2 hours perfusion with
various saline solutions such as Krebs' and McEwen's
solutions.
It is not easy to make valid comparisons between the
amount of PGE2 required to produce pharmacological effects
and the amount released in response to nerve stimulation.
The critical concentration is that present in the inter¬
stitial fluid around the sympathetic nerve endings. Intra¬
arterial infusion may be an inefficient way of applying
exogenous PGE2 to the target organ. On the other hand, the
saline-perfused kidney may well have been more permeable
to the passage of exogenous PGE2 through the vascular wall.
In the original experiments of Davies and Withrington (1968)
on the dog spleen, prostaglandins were infused into the
blood-perfused organ - it may well be that their negative
results can be attributed to the lack of such increased
permeability under the more physiological conditions used
for that preparation. It may be argued that the less
physiological conditions pertaining in the rabbit kidney
experiments of Frame and Hedqvist permitted a physiological
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response to be observed because the abnormal permeability
of the vasculature allowed the PGE2 to reach its target
despite an unphysiological route of administration.
The route of administration and the dose used to
demonstrate the luteolytic actions of PGF2a in rats and
guinea-pigs are even more removed from the physiological
mode of release. Milligram doses of PGF2a were injected
intra-peritoneally. On the other hand, the experiment was
in vivo and the luteolysis was observed under otherwise
physiological conditions. It would be useful to see whether
intra-uterine implantation of PGF2a in some slow release
preparation (analogous to that used in the indomethacin
experiments described in this thesis) would mimic more
closely the physiological release and produce effects on the
ovary with very much smaller doses than those that had to
be given systemically.
Each of these two pharmacological responses was obtained
in the same preparation and species as were used for the
studies involving release and its blockade. This greatly .
strengthens the hypothesis concerned with their physiological
roles.
The pharmacological effects of seminal prostaglandins
have been subjected to nearly as much speculation as experi¬
ment. Certainly they have effects upon various smooth
muscle preparations of both the male and female reproductive
tracts (Eliasson, 1959).
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(b) Identification of Prostaglandins Released In all
instances the biological fluids have been extracted by
methods designed to separate polar acidic lipids like the
prostaglandins from natural substances of other chemical
types - bases, non-lipids, neutral lipids etc. The par¬
tition procedure, by its selective extraction, itself pro¬
vided some evidence of identification. Chromatographic
evidence from silicic acid columns or silica gel plates
provided further evidence - if the extracted material
differed in its chromatographic behaviour from a known
prostaglandin it was strong negative evidence of identifi¬
cation. Thus the material extracted from incubates of
distended uterine horns could not be PGE2 because its
chromatographic behaviour on silicic acid was clearly
different. It could be PGF2a t>u"t it could also be some
other acidic lipid that happened to share the chromato¬
graphic behaviour of PGF2C[ (e.g. the urinary metabolite of
PGF2£X in guinea-pigs).
Similarly, strong negative evidence can be obtained
from quantitative parallel biological assays (Chang and
Gaddum, 1933). Disagreement between results on different
preparations shows that the test material and the pure
standard are not the same. Agreement between different
assays provides some evidence that the two substances are
identical - the greater the number of assays the stronger
the evidence (Gaddum, 1955); but again the positive evi¬
dence is never absolutely conclusive (Horton and Main, 1967).
In both physico-chemical investigations and in bioassay the
presence of impurities in the extracts may confuse the pic¬
ture; chromatographic behaviour, for example, may be altered
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dramatically in the presence of interfering substances.
This problem may be overcome by adding radioactive tracer
prostaglandins to the biological material before extraction
as was done routinely in the present investigations on the
kidney and the seminal fluid.
The most unequivocal means available for the identifi¬
cation of submicrogram quantities of the prostaglandins is
combined GLC/MS. This was used throughout this study.
Both GLC behaviour (retention time) and mass spectral data
contribute to the evidence of identification. Provided
that sufficient material is available for analysis, the
chief difficulties are to distinguish between stereoisomers
(e.g. PGF2a and PGF2p) and between closely similar substances
(e.g. PGF2a and PGF1CI). GLC separation can be achieved pro¬
vided that the column conditions are suitable - mass spectral
differences may be convincing where compounds differ by as
little as 2 a.m.u. provided that the instrument is accur¬
ately calibrated. Mass spectral differences between two
stereoisomers are often minimal in which case distinction
between them has to rest upon other evidence (for example
GLC, biological assay, TLC separation or the preparation
of a suitable derivative (e.g. the butylboronide of PGF2CC).
(c) Measurement Prostaglandins in this study were measured
by three different techniques - spectrophotometry, biological
assay and GLC/MS. Provided that amounts are adequate (as
in semen) and provided that the prostaglandin yields a
suitable chromophore (e.g. PGE2) spectrometry gives accurate
122
results. The addition of tracer provides a built-in
method for correcting the results for recovery. It
will be noted that recoveries in all three investigations
were lower than many people would regard as ideal. This
problem was studied at considerable length but despite
modifications to the scheme of extraction these recoveries
were the best that could be achieved. They were, however,
consistent and fell within a reasonably narrow range. It
may be noted that these recoveries do raise doubts about
the value of those investigations reported in the literature
in which no attempt at all has been made to check or correct
for this source of error.
In the kidney and uterus work, the final assays were made
biologically on material which had been highly purified -
extensive partition followed by chromatography. Virtually
all the biologically-active material present in these final
extracts possessed physico-chemical properties like the
prostaglandins and usually it could be defined even more
narrowly on the basis of chromatographic separation as
PGE-like, PGF-like etc.
With the introduction of radioimmunoassay which has
numerous advantages, such as sensitivity, speed and precision,
it has become fashionable to dismiss biological assay as
out-moded and non-specific. The critics point out that the
bioassays frequently respond to natural substances which are
chemically very diverse (e.g. amines, peptides and nucleo¬
tides as well as prostaglandins). This criticism may
be justifiable if the biological assay is done using crude
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biological extracts but in all the experiments described
here such non-prostaglandin substances of natural origin
are discarded during the partition or separated by the
chromatography, both of which precede the biological assay.
In fact, biological assay often has advantages of selec¬
tivity, not necessarily possessed by radioimmunoassay. A
very slight change in chemical structure may be sufficient
to diminish or qualitatively change the pharmacological
activity of a molecule, whereas cross-reactivity with the
antibody used in the radioimmune method may be scarcely
affected. Certainly, radioimmunoassay has many advantages
over biological assay, superior specificity is not necessarily
one of them.
Quantitation using conventional GLC/MS as in this study
depends primarily upon the size of the GLC peak which measures
total ion current. This has the advantage that a full mass
spectrum can be taken at the top of the peak to provide con¬
clusive identification of the molecule being measured.
The method has the disadvantage that the amount which can
be detected by the total ion current size restricts the
sensitivity of the method. Multiple ion detection is a
variation of the technique which could not be used with
the GLC/MS equipment available at the time of this study.
It provides evidence of identification based upon one or
more of the abundant MS peaks the size of which is measured
in terms of a deuterated prostaglandin used as an internal
carrier. The disadvantage of the method is that the identi¬
fication is less than conclusive unless a full mass spectrum
is obtained. In all the investigations described in this
study full mass spectra were taken.
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The advantages and disadvantages of these different
methods of measurement have been discussed more fully
elsewhere (Horton, 1976b).
(d) Inhibition of prostaglandin biosynthesis or action The
effects of aspirin and indomethacin as inhibitors of the
enzyme, fatty acid cyclo-oxygenase, a component of the prosta¬
glandin synthase complex is now undisputed (Vane, 1971 and
many subsequent papers). The effects of aspirin on such
synthesis in man are clearly apparent from the work described
here on seminal prostaglandin levels. Nevertheless, the
possibility that these drugs may have actions on other
systems, including other enzymes, must be considered.
Responses which follow the administration of these drugs may
not necessarily be attributable therefore to blockade of
prostaglandin synthesis.
In the experiments on renal adrenergic nerve endings
clear-cut evidence of the blockade of prostaglandin release
hence biosynthesis (Davies, et al., 1968; Piper and Vane,
1971) was obtained. The vascular changes which ensued may
well have resulted from such blockade but other explanations
cannot be ruled out. In the luteolysin study, the effects
on indomethacin were clear-cut,closely resembling those
which follow hysterectomy. No direct evidence was obtained
that indomethacin was in fact inhibiting the biosynthesis of
PGF2a in the uterus, though it is well documented from in
vitro studies that such an inhibition was highly likely to
have occurred.
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Similarly the effects following active immunization
against PGF2CC were clear cut, again resembling those follow¬
ing hysterectomy, but there was no conclusive evidence that
the presumed blockade of PGF2CC was occurring in the local
circulation between the uterus and the ipsilateral ovary.
Other possibilities have been considered above (p.107).
How Conclusive is the Experimental Evidence Presented for
Physiological Roles of the Prostaglandins?
(a) Prostaglandin E2 as a modulator of adrenergic nerve
transmission
Taking into account the various snags and alternative
explanations discussed already, it may be argued that the
evidence is still not conclusive. There can certainly be
no doubt that prostaglandins are released from the kidney in
increased amounts during stimulation of the renal nerves which
are adrenergic, that this release is abolished by indomethacin
and that two of these prostaglandins (PGE2 and PGF2a) have
been identified unequivocally in the appropriate extracts.
There is also no doubt that in the saline-perfused rabbit
kidney intra-arterial infusion of PGE2 reduces transmitter
output in response to stimulation of the renal nerves, though
it may be argued that the evidence is weakened by the use of
a saline-perfused preparation and by the route of administration
which is certainly very different from the physiological route -
but it was the best that could be devised. The vascular changes
following indomethacin are certainly compatible with the
enhancement of sympathetic activity which would result if the
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influence of an inhibitory modulator, such as PGE2, were
removed. More precise measurements of the vascular changes
in the kidney are needed to strengthen this particular piece
of evidence.
As already discussed, the hypothesis, true as it may be,
for PGE2 in the rabbit kidney, does not necessarily extend
to all adrenergic nerve endings. The discrepancy between
the output experiments in the dog and cat spleen (Davies,
et al., 1968; Bedwani and Millar, 1975) and between the
pharmacological experiments on the dog and cat spleen (Davies
and Withrington, 1968; Hedqvist, 1971) have been highlighted
previously (Horton, 1973). Particularly relevant are the
findings of Bedwani and Millar (1975) who confirmed the out¬
put of prostaglandins from the dog spleen on nerve stimulation
but were unable to obtain any convincing evidence for the
release of prostaglandins from the cat spleen. Dubocovitch
and Langer (1975) were able to demonstrate prostaglandin
release only after the cat spleen had been saline-perfused
for several hours. Moreover, abolition of this output by
indomethacin did not affect responses to nerve stimulation
nor the amount of noradrenaline overflow, although, like
Hedqvist, they were able to demonstrate that exogenous PGE2
inhibits transmitter release.
Unfortunately, as it stands, the hypothesis does not
explain all the observations, namely the release of PGF2a
and of a PGA-like compound simultaneously with PGE2 in res¬
ponse to nerve stimulation. It may be argued that the output
of these substances need not detract from the evidence support¬
ing PGE2 as a modulator, but the hypothesis may need future
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modification to account for the possible role of these
other prostaglandins at adrenergic nerve terminals.
It seems reasonable to conclude that PGE2 has a physio¬
logical role as an inhibitor of noradrenaline output during
adrenergic nerve stimulation in the rabbit kidney but that
this function does not necessarily extend generally to all
adrenergic nerves and relates only to a function for PGE2.
(b) Role of Prostaglandins in Human Semen
The presence in semen of high concentrations of pharma¬
cologically-active substances like the prostaglandins suggests
but by no means proves that seminal prostaglandins have a
physiological role. It is easy to speculate that they may
be involved with the control of sperm transport in the male
and/or female reproductive tracts by an action on smooth
muscle organs such as the vas deferens or the oviduct. The
only real evidence of a function comes from comparisons of
fertile and infertile males in which infertility cannot be
accounted for by other factors (low sperm count etc.).
Such evidence «as first put forward by Hawkins and Labrum
(1961 ) and more convincingly (because the methodology of
estimation had improved) by Bygdeman et_ al_. , 1970. Both
claimed that low prostaglandin levels were associated with
such cases of unexplained infertility.
The present study has shown that aspirin in high dosage,
such as might be used in the treatment of acute rheumatic
episodes, does greatly reduce prostaglandin levels in human
seminal plasma. In theory a long-term trial could be
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mounted in which male volunteers would be given aspirin
whilst the effects on fertility were monitored. In
practice, it would be difficult and possibly hazardous to
conduct such a trial - volunteers would be hard to obtain
for such a long-term study, the effects of aspirin on
sperm (and hence offspring should fertilization occur) are
unknown and most significantly, from the evidence of this
short-term study, the effects of the doses of aspirin
required might have potentially lethal effects over a
longer period.
If a less toxic inhibitor of prostaglandin synthase
or one which more selectively blocked the enzyme in the male
reproductive tract were forthcoming, it is possible that
such a trial might be feasible and, on a more speculative
note, that such a drug might be used as a contraceptive
agent in the human male.
(c ) The Role of PGForY as the Guinea-pig Luteolytic Hormone
The accumulation of evidence in favour of the hypothesis
that the guinea-pig uterus produces PGF2CC towards the end of
the oestrous cycle and secretes this to act upon the corpora
lutea causing their regression and so termination of the
cycle, has been summarized above (p.110). The deficiencies
in this hypothesis are easily detectable. First, there is,
as yet, no explanation as to how (or indeed whether) the PGF2a
released into the uterine venous blood reaches the ipsilateral
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ovary to act upon the corpora lutea there. It may be a
vascular route, although examination of the blood vessels
under a dissecting microscope failed to reveal any evidence
for a relationship between the ovarian artery and the utero-
ovarian vein as is evident in the sheep (McCracken, 1971; McCracken,
Baird and Goding, 1971). It might eventually prove feasible
to cannulate the ovarian artery so as to collect samples of
blood supplying that organ,for PGF2a determinations. Alter¬
natively, the local route may be via the lymph, the lumen of
the reproductive tract or a so-far undetected vascular con-
nection between uterus and ovary. Although the biochemical
mode of action of PGF2a as a luteolytic substance is still
not clearly understood (see Horton and Poyser, 1976), this
need not detract from the hypothesis, provided that PGF2a
really does have a luteolytic action within the concentration
range likely to be found in the ovary under physiological
conditions.
Although the evidence from the immunization experiments
does not conclusively prove that the site of neutralization
of the endogenous PGF2a occurred in utero-ovarian circulation
and although direct evidence as to the mode of action of
intra-uterine indomethacin is also lacking, the accumulation
of evidence concerning a physiological role for PGF2(X as
the uterine luteolytic hormone in the guinea-pig is considered
to be very compelling. Just how general this phenomenon is
within the Animal Kingdom has been discussed by Horton and
Poyser (1976). Certainly there is excellent evidence for
such a role for PGF2a in the sheep (McCracken, et <rl. , 1972);
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there is also evidence in other domestic farm animals as
well as in the pseudopregnant rat and rabbit. Whether
local control mechanisms of this nature are found at other
sites requires further consideration - for example sub¬
stances released from the spleen or the gastro-intestinal
tract may act as local hormones on the liver whilst sub¬
stances released peripherally may exert a humoral effect
on the frog kidney via the renal portal veins.
Other functions of prostaglandins in the urogenital tract
Finally, brief consideration will be given to other pos¬
sible functions of prostaglandins in organs of the urogenital
tract. In the kidney a prostaglandin may be implicated in
the mechanism of autoregulation (Herbaczynska-Cedro and
Vane, 1973), whilst a role as the renal antihypertensive
lipid has long been debated (see Horton and Ungar, 1974).
Since prostaglandins have both natriuretic and diuretic
activity, one of them could be implicated in the mode of
action of the postulated natriuretic hormone described by
de Wardener (de Wardener, Mills, Clapham and Hayter, 1961)
or possibly be identical with the natriuretic hormone itself.
Prostaglandins interact with the renin-angiotensin
system and have been involved in control of renin release
(Flamenbaum and Kleinman, 1977; McGiff and Malik, 1976).
A similar inter-relationship between renal prostaglandins
and erythropoeitin may be envisaged.
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None of these other renal functions is necessarily
related to the proposed function at adrenergic nerve ter¬
minals investigated here, although an inter-relationship
between sympathetic nervous system activity and other
facets of renal function must not be excluded.
The seminal prostaglandins present an even more diffi¬
cult problem although their many pharmacological actions on
reproductive organs all seem logically to point to some
influence on fertility. Actions of prostaglandins on both
smooth muscle and glands of female reproductive tract have
been reported. Moreover, prostaglandins act upon uterine
smooth muscle, the cervix and the oviduct (see Horton, 1969).
Some of these potential targets in the female reproductive
tract could be reached by local diffusion of prostaglandins
from the ejaculate deposited in the posterior fornix.
Other targets, notably the oviduct, could probably only be
influenced by seminal prostaglandins if some means of trans¬
porting them so far is available. It is established (Horton,
Main and Thompson, 1965) that PGE, is absorbed from the vagina
in rabbits in amounts sufficient to affect oviduct smooth
muscle and similar vaginal absorption has been reported in human
female volunteers (Eliasson and Posse, 1965). Such mechanisms
are of considerable biological interest and it would be of
interest to know whether prostaglandins act as exohormones or
even pheromones in an analogous way in other species.
Uterine prostaglandins formed in the endometrium may well
have other functions, notably at the time of implantation
(Phillips and Poyser, 1979) and in the pregnant animal (formed
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by the uterus or uterine contents) as an oxytocic stimulus
in parturition (see Karim and Hillier, 1975; Flint and
Hillier, 1975).
It seems clear that the role of prostaglandins in
ovulation is a local effect brought about by the ovarian
prostaglandins themselves. Finally, a role of locally
produced prostaglandins in controlling oviduct tone (Horton
and Main, 1963) is likely to involve interesting inter¬
relationships with oestrogens and progestogens which control
the hormonal status of that tissue and with the adrenergic
terminals of neurones in the hypogastric nerve, stimulation
of which causes pronounced changes in oviduct tone.
It may well be that further research on the oviduct
is needed to solve these intriguing inter-relationships
between the adrenergic nervous system, the ovarian hormones
and the prostaglandins which have been studied separately
in the research work reported in this thesis.
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